Maryam Omran1Elizabeth K. Belcher1Nimish A. Mohile1
Shelli R. Kesler2Michelle C. Janelsins1
Andrea G. Hohmann3
Ian R. Kleckner1*- 1University of Rochester Medical Center, Rochester, NY, United States
- 2The University of Texas at Austin, Austin, TX, United States
- 3Psychological and Brain Sciences, Program in Neuroscience and Gill Center for Biomolecular Science, Indiana University Bloomington, Bloomington, IN, United States
Chemotherapy-induced peripheral neuropathy (CIPN) is a common, debilitating, and dose-limiting side effect of many chemotherapy regimens yet has limited treatments due to incomplete knowledge of its pathophysiology. Research on the pathophysiology of CIPN has focused on peripheral nerves because CIPN symptoms are felt in the hands and feet. However, better understanding the role of the brain in CIPN may accelerate understanding, diagnosing, and treating CIPN. The goals of this review are to (1) investigate the role of the brain in CIPN, and (2) use this knowledge to inform future research and treatment of CIPN. We identified 16 papers using brain interventions in animal models of CIPN and five papers using brain imaging in humans or monkeys with CIPN. These studies suggest that CIPN is partly caused by (1) brain hyperactivity, (2) reduced GABAergic inhibition, (3) neuroinflammation, and (4) overactivation of GPCR/MAPK pathways. These four features were observed in several brain regions including the thalamus, periaqueductal gray, anterior cingulate cortex, somatosensory cortex, and insula. We discuss how to leverage this knowledge for future preclinical research, clinical research, and brain-based treatments for CIPN.
Introduction
Chemotherapy-induced peripheral neuropathy (CIPN) is a highly prevalent and severe toxicity of many widely used chemotherapy drugs including platinum-based agents (oxaliplatin, cisplatin, carboplatin), taxanes (paclitaxel, docetaxel), vinca alkaloids, proteasome inhibitors, and thalidomide analogues (Staff et al., 2017; Chan et al., 2019). These neurotoxic anti-cancer agents are used to treat breast, lung, cervical, prostate, ovarian, testicular, gastrointestinal, and blood or bone marrow cancers. CIPN is a dose-limiting toxicity, meaning that it can result in dose interruptions, subtherapeutic dosing, or discontinued therapy, in turn negatively impacting cancer progression (Lyman, 2009). Acute symptoms of CIPN appear in the hours and days after an infusion (Reeves et al., 2012; Argyriou et al., 2013; Pachman et al., 2015) whereas persistent symptoms occur in approximately 68% of patients one month following completion of chemotherapy and 30% of patients five months later (Seretny et al., 2014). On average, patients with CIPN require 12 more outpatient visits, three more hospital days, and $17,000 USD more in medical expenses than matched patients without CIPN (Pike et al., 2012). Thus, CIPN can severely impair physical, social, emotional, functional, financial, and occupational aspects of life.
We use the term CIPN to encompass patient-reported symptoms, clinical signs, and mechanistic features (e.g., neurobiological factors that cause or exacerbate CIPN), as opposed to a narrower definition referring only to the damage, dysfunction, and death of peripheral neurons. The symptoms of CIPN are primarily felt in the hands and feet with some combination of numbness, tingling, shooting or stabbing pain, burning pain, cramping, and hypersensitivity to cold temperatures (e.g., cold weather, touching something cold) (Staff et al., 2017; Chan et al., 2018). The clinical signs and symptoms include loss of tactile or vibration sensitivity, cold-induced pain in the hands, feet, mouth, and throat (cold allodynia), changes in walking gait, weakness, loss of balance, orthostatic hypotension, and sometimes changes in peripheral sensory nerve conduction (e.g., reduced sensory nerve action potential amplitudes) (Staff et al., 2017). The mechanistic features putatively include loss of intraepidermal nerve fibers, mitochondrial dysfunction, neuroinflammation, oxidative stress, and other features mentioned below (Flatters et al., 2017; Chan et al., 2019; Zajaczkowska et al., 2019). There is no gold standard assessment for identifying CIPN, but its diagnosis depends on patient history, symptoms, neurologic examination and type and dose of chemotherapy (Loprinzi et al., 2020; Wasilewski and Mohile, 2020).
There are only minimally effective methods to treat or prevent CIPN despite over 20 years of research and nearly 100 clinical trials in humans (Hershman et al., 2014; Loprinzi et al., 2020). In fact, the only recommended treatment is the drug duloxetine (Loprinzi et al., 2020), which only mildly improves CIPN pain (Smith et al., 2013). There are also several promising yet unproven interventions to treat or prevent CIPN, such as exercise (Kleckner et al., 2021a; Kleckner et al., 2021b), acupuncture, scrambler therapy (peripheral nerve stimulation), cryotherapy, cannabinoids, and tricyclic antidepressants (Loprinzi et al., 2020). A recent report from the 2017 National Cancer Institute Clinical Trials Planning Meeting on CIPN concluded that the lack of effective CIPN treatments is partly due to an incomplete understanding of the pathophysiological mechanisms of CIPN (Dorsey et al., 2019). Therefore, herein we investigate a novel perspective on the pathophysiology of CIPN by focusing on the role of the brain in CIPN, as opposed to the peripheral nervous system.
The majority of research on CIPN mechanisms has focused on primary afferents of the peripheral nervous system. This rapidly growing body of research is rigorous and utilizes a variety of preclinical non-human animal models of CIPN. Typically, this involves rats or mice without cancer who repeatedly receive chemotherapy (usually oxaliplatin or paclitaxel) across several days or weeks to mimic how chemotherapy is delivered to human patients with cancer. This is combined with assessments of clinical signs of CIPN in the paws such as cold allodynia, mechanical allodynia, and mechanical hyperalgesia (Bonhof et al., 2019). Collectively, this research implicates multiple mechanisms documenting how chemotherapy causes peripheral nerve damage, dysfunction, and death (Flatters et al., 2017) including: (1) altered expression of ion channels and receptors that cause neuronal hyperactivity, (2) the innate immune response and inflammation, (3) mitochondrial dysfunction, and (4) changes in cell-signaling pathways such as G-coupled protein receptors (GPCRs) and mitogen-activated protein kinases (MAPK; see Table 1 for more details and citations). These are just some of the known mechanisms studied at the peripheral and spinal nerve levels in relation to CIPN, and other mechanisms likely contribute as well. Some of these same mechanisms extend to the brain (e.g., hyperactivity, inflammation, GPCR) with some important differences (e.g., the role of large-scale brain networks). Moreover, peripheral pathology seen in CIPN can lead to maladaptive responses in the brain that contribute to CIPN even if chemotherapy drugs do not enter the brain, as we discuss below. We postulate that knowledge of both peripheral and brain-based mechanisms can more holistically advance the study of CIPN.
TABLE 1. Overview of key pathways in the peripheral nerves implicated in CIPN.
Unfortunately, mechanism-based treatments for CIPN have not yet translated into many effective treatments in humans (Hu et al., 2019). For example, acetyl-l carnitine was a promising agent that reduced CIPN and improved peripheral nerve function in rodents via known effects on mitochondria (De Grandis, 2007), but a phase III randomized controlled trials (RCTs) in 409 patients found acetyl-l-carnitine worsened CIPN in humans (De Grandis, 2007; Hershman, Unger et al., 2013). A similar pattern was observed with the drug pregabalin, which successfully reduced CIPN in rodents by binding to voltage-gated calcium ion channels (Peng et al., 2012; Aoki et al., 2014), which are over-expressed in dorsal root ganglia (DRG) in CIPN (Gauchan et al., 2009). However, pregabalin failed to significantly reduce CIPN in a 199-patient randomized controlled trial in humans (De Andrade et al., 2017). Given the current lack of effective human treatments for CIPN derived from knowledge of peripheral pathways, research on CIPN needs a paradigm shift to focus on novel mechanisms.
We hypothesize that the central nervous system (CNS), and particularly the brain, has a previously under-recognized role in the pathophysiology of human CIPN (Figure 1). This novel perspective can dramatically shift our understanding of CIPN, inform new avenues of research, and ultimately accelerate the development of new and more effective clinical methods to diagnose, treat, and prevent CIPN. Our perspective is consistent with the fact that the only proven treatment for CIPN (duloxetine) acts in the brain as a serotonin-norepinephrine reuptake inhibitor (Smith and Nicholson, 2007; Smith, Pang et al., 2013). The importance of the brain is also emphasized by the well-known poor correlations between peripheral nerve conduction results and patient symptoms of CIPN (Cavaletti et al., 2011; Sharma et al., 2015). This apparent discrepancy is actually consistent with a massive body of literature from psychology and neuroscience that human feelings (including symptoms) are not flawless reflections of peripheral sensory input but instead feelings are a loose interpretation or prediction merely tailored by peripheral sensory input (Kleckner and Quigley, 2015; Siegel et al., 2018; Barrett and Satpute, 2019). In addition, the brain may play a role in CIPN even if neurotoxic chemotherapy does not enter the brain; indeed, the brain undergoes compensation and reorganization due to peripheral damage in other conditions such as phantom limb pain (Makin and Flor, 2020). Several studies have hypothesized or studied brain mechanisms in CIPN in humans (Weng et al., 2003; Boland et al., 2014; Dougherty, 2016; Nudelman et al., 2016; Prinsloo et al., 2017; Kleckner et al., 2018), and in rodents (e.g. (Thibault et al., 2012; Ferris et al., 2019)). Yet, to date, no papers have synthesized the current state of knowledge regarding the role of the brain in CIPN.
FIGURE 1. Schematic of our hypothesis that CIPN symptoms are caused by (1) brain sensitization and compensation due to peripheral and spinal nerve damage and dysfunction, which is shown in the red box and is the focus of our novel review, plus two more well-studied phenomena: (2) spinal sensitization and compensation, and (3) peripheral nerve damage. Our hypothesis does not depend on whether chemotherapy enters the brain (green dashed arrows) for changes in the brain to contribute to CIPN symptoms. Image adapted from innerbody.com.
The goal of this review is to begin to answer two questions that have not been comprehensively addressed in the literature: (1) does the brain play a prominent or even causal role in the pathophysiology of CIPN (i.e., CIPN as a syndrome, not just the peripheral neuropathy itself)? and (2) how can we leverage knowledge of the brain’s role in CIPN to accelerate basic research, clinical research, and diagnostics, treatment, and prevention of CIPN? We performed a scoping review (Munn et al., 2018) to synthesize evidence from published studies in humans that assessed relationships between CIPN severity and brain measures (e.g., activity, blood flow) and studies in non-human animals that used experimental manipulations of the brain and observed its effects on CIPN. We synthesized the results of these papers at the molecular and brain network/systems level. Finally, we consider implications for preclinical research, clinical research, and clinical treatment of CIPN informed by the proposed mechanisms of brain involvement.
Methods
We conducted a literature review on brain interventions in CIPN using PubMed. Our criteria were as follows: each study (1) measured CIPN signs or symptoms, (2) included human or non-human primate imaging OR an intervention delivered to the brain or spinal cord, (3) was written in English, and (4) was published before January 2021. We began with two PubMed searches: (1) (oxaliplatin OR paclitaxel OR docetaxel OR cisplatin OR bortezomib OR thalidomide) AND (insula OR insular OR cingulate OR cortex OR cortical OR amygdala OR somatosensory OR thalamus OR brain) NOT kidney NOT renal NOT nephrotoxicity, and (2) (ICV or intracerebroventricularly) AND neuropathy AND (oxaliplatin OR carboplatin OR paclitaxel OR docetaxel), and then we identified additional papers of interest by searching papers that cited the papers from our PubMed search.
We conducted exhaustive searches of the literature on the role of the human/primate brain in CIPN and of brain interventions in CIPN. However, we did not conduct an exhaustive search of all spinal cord intervention papers; rather, we selected papers that also mentioned the role of the brain, per our literature search criteria.
Results and Discussion
Human and Non-human Primate Brain Imaging (5 Studies; Table 2)
Our literature search found three published studies of the brain and CIPN in humans, and two studies in macaque monkeys (details provided in Table 2). The human studies were fairly heterogeneous in terms of patients (breast, multiple myeloma, mixed cancers), design (comparing pre- and post-chemotherapy, case-control of patients with vs. without CIPN, RCT using EEG neurofeedback), and sample size (range of 7–62). Three studies used fMRI in response to an applied painful stimulus, one study assessed resting blood perfusion with MRI, and one study assessed resting power in various frequency bands using EEG.
TABLE 2. Human and non-human primate studies of the brain and CIPN.
We identified three common themes across these five papers. First, CIPN is associated with brain hyperactivity in response to painful stimuli in sensory regions (S2/insula; Boland et al., 2014; Shidahara et al., 2019; and Nagasaka et al., 2017)1 and in the posterior portion of the default mode network (DMN (Raichle, 2015); specifically, the ventral precuneus; Boland et al., 2014) but reduced activity in anterior DMN (superior frontal gyrus, strongly connected to the ACC and mid cingulate cortex (Li et al., 2013; Boland et al., 2014). Second, CIPN is associated with greater resting perfusion in the DMN (superior frontal gyrus, cingulate; medial frontal gyrus; Nudelman et al., 2016) and greater gray matter densities in the same regions (Nudelman et al., 2016). Third, in terms of interventions, reduction of CIPN symptoms is associated with reduction in brain activity in the insula (Shidahara et al., 2019; Nagasaka et al., 2017; and Prinsloo et al., 2017). Duloxetine reduced the brain response to cold-induced pain in S2/insula (Shidahara et al., 2019 and Nagasaka et al., 2017), and reduction in CIPN pain from neurofeedback was associated with a reduction in insula activity at rest (Prinsloo et al., 2017) as well as a reduction in resting β power (13–45 Hz) in the bilateral parietal cortices and midline regions (including the ACC and DMN; Prinsloo et al., 2017).
The aforementioned studies suggest that hyperactivity in the brain (particularly the insula) is positively correlated with CIPN severity. However, because of the observational nature of these studies,2 it is unclear whether brain changes causally contribute to changes in CIPN symptoms, or whether the brain changes are merely epiphenomenal. To explore how changes in the brain might cause changes in CIPN symptoms, we next reviewed studies in non-human animals testing interventions to the brain itself, with results supported by interventions to the spinal cord.
Overview of Rodent Studies With CNS Interventions (24 Studies)
Table 3 shows all 16 studies using brain interventions from our literature search. Six studies used injections of specific receptor agonists or antagonists or other compounds applied to a localized brain region, nine used intracerebroventricular (ICV) injections, and one used ex-vivo slices from a specific brain region. All studies in Table 3 used either oxaliplatin or paclitaxel. Most used mice or rats as their animal model (often male), while one used monkeys. The brain regions investigated include the periaqueductal gray (PAG), thalamus, anterior cingulate cortex (ACC), insula, secondary somatosensory cortex (S2), and sometimes less specifically defined regions such as “frontal cortex” (likely including the ACC) or the entire cortex. Brain measures included fMRI, synaptic potentials, and PCR and western blot analysis on post-mortem brain sample homogenates.
TABLE 3. Studies that test interventions to the brain that cause or treat CIPN symptoms.
Table 4 includes the eight papers using interventions to the spinal cord via intrathecal injection or cell transplant. In comparison to studies of brain interventions, the spinal cord intervention papers utilized a wider variety of chemotherapy agents including oxaliplatin, paclitaxel, and vincristine. Additionally, Table 4 papers focused on more detailed, molecular-level analyses of CNS changes. Across all studies, CIPN signs and symptoms were evaluated using various tests including the Electronic von Frey, tail immersion test, hot and cold plate tests, paw pressure tests, and rotarod tests. Table 4 provides in depth details regarding the methods and outcomes of these studies, while the below results section provides a broader summary of the main results.
TABLE 4. Papers that test interventions to the spinal cord that cause or treat CIPN symptoms.
Overall, we identified four themes: brain hyperactivity, reduced GABAergic inhibition, inflammation, and GPCR/MAPK signaling. We discuss how these themes are supported by the studies and their implications for clinical research and ultimately treating and preventing CIPN in patients.
Hyperactivity
Neurotoxic chemotherapeutic agents lead to chronic hyperactivity within specific brain regions or as an overall state of the CNS. Hyperactivity was detected in the S2 and insula following oxaliplatin using fMRI to measure brain activity in response to cold stimulation of the tail (Nagasaka et al., 2017). Oxaliplatin produced hyperactivity in the somatosensory, cingulate, and motor cortices as measured by increased p-Erk-IR neurons, a marker of neuronal activity (Thibault et al., 2012). Finally, oxaliplatin produced hyperactivity as measured by field excitatory post synaptic potentials measured in post-mortem ACC slices (Nashawi et al., 2016).
These studies investigated different mechanisms underlying increased brain activity. For instance, voltage-gated potassium channels cause hyperpolarization, thereby requiring an increased stimulus for a neuron to fire an action potential. Oxaliplatin downregulates expression of potassium channel Kv2.2 in the somatosensory cortex, thereby requiring a smaller stimulus for neuronal firing (Thibault et al., 2012). Moreover, experimentally downregulating Kv2.2 in the somatosensory cortex (thereby removing the inhibitory mechanism) caused hyperactivity and CIPN symptoms in chemotherapy-naïve rats (Thibault et al., 2012). This is consistent with another study in rodents showing that systemic K+ channel knockout causes mechanical and cold sensitivity (Castellanos et al., 2020). Hyperactivity might also be caused by changes in voltage-gated sodium channel expression, as shown in the ACC in response to paclitaxel (Masocha, 2016), or by a reduction in GABA, an inhibitory neurotransmitter and the topic of the next theme (Nagasaka et al., 2017; Nashawi et al., 2016).
Neurotoxic chemotherapy also produced hyperexcitability in neurons of the spinal cord and the DRG, which bridge the peripheral nervous system and the spinal cord. One study found an increase in P2X7R-dependant glutamate release from cerebrocortical synaptosomes following oxaliplatin treatment; glutamate is the major excitatory CNS neurotransmitter, and its release was eliminated by P2X7R antagonists delivered to the spinal cord (Mannelli et al., 2015). A more positive resting membrane potential and a greater frequency of firing (i.e., hyperactivity) was observed in SOM+ excitatory interneurons in the outer lamina of the dorsal horn following paclitaxel treatment; experimentally blocking the IL-17 receptor reduced both hyperactivity and CIPN symptoms (Luo et al., 2019).
Taken together, CNS hyperactivity occurs in CIPN and correlates over time with changes in CIPN symptoms. Hyperactivity in the PAG, thalamus, ACC, and somatosensory cortex might be one of the final common pathways to symptoms of CIPN, as these brain regions support interoception (Kleckner et al., 2017), the processing and perception of sensations from the body (Craig, 2002; Khalsa et al., 2018). It seems plausible that brain amplification of peripheral inputs (i.e., hyperactivity) could help explain CIPN symptoms of hyperalgesia, an increased sensitivity to pain, and allodynia, the experience of pain to normally non-painful stimuli. Clinically, because brain hyperactivity is easy to measure during fMRI scanning or EEG recording, it could serve as an objective biomarker for CIPN used for diagnosis or as an endpoint in a clinical trial (i.e., a surrogate or target for treatment). Future research can explore whether specific patterns of brain hyperactivity (e.g., in the PAG vs. thalamus vs. insula vs. ACC) can help distinguish different subtypes of CIPN that might respond differently to different treatments or predict different natural histories of symptom escalation and recovery.
Decreased GABAergic Inhibition
A reduction in GABA levels in the brain may contribute to CIPN by decreasing inhibitory signaling, whereas experimental activation of the GABAergic system reduces and/or reverses CIPN symptoms. A decrease in GABA in the thalamus and dorsolateral PAG (dl-PAG) was reported after oxaliplatin treatment in rats that was accompanied by signs of CIPN (Ferrier et al., 2015; Xu et al., 2018). One study experimentally activated GABAA receptors specifically in the dl-PAG, which decreased CIPN symptoms and reduced PAG hyperactivity (Xu et al., 2018). Another paper experimentally activated the GABAA receptor via injection of muscimol into the insula/S2, which reversed hyperactivity in the insula/S2 during cold-stimulation as measured by fMRI and reduced CIPN symptoms in oxaliplatin-treated monkeys (Nagasaka et al., 2017). Similarly, one study showed that a bath application of GABA or a GABAB receptor agonist in rats ex vivo ACC slices attenuated the increase in field excitatory post synaptic potentials, thereby reducing hyperactivity (Nashawi et al., 2016). GABAergic mechanisms in the brain have also been shown to mediate effects of compounds that reduce CIPN pain, as antagonizing the GABAB receptor in the brain via ICV injection blocked the analgesic effects of CDP-Choline (Kanat et al., 2013).
Alterations in GABAergic signaling in the spinal cord may also play a role in CIPN. Transplant of GABA-producing cells within the spinal cord reversed paclitaxel-induced CIPN symptoms in mice with an intact GABA transporter but not in mutant mice missing a GABA-releasing transporter (Braz et al., 2015). GABA receptor activity was reduced and GABA transporter expression levels increased in the dorsal horn of paclitaxel-treated mice, suggesting increased GABA reuptake in the dorsal horn and decreased GABAergic inhibition (Yadav et al., 2015). Inhibiting the GAT-1 transporter, thereby allowing further release of GABA and enhancing neural inhibition, reduced paclitaxel-induced neuropathic pain. Therefore, directly increasing GABA levels or stimulating the GABA receptors enhanced inhibitory signals and eliminated CIPN symptoms. GABAergic pathways in the spinal cord are also involved in the treatment of CIPN symptoms by analgesics. Specifically, oxycodone, which upregulated GABA receptor mRNA in the DRG, had longer lasting analgesic effects than morphine in rats with vincristine-induced CIPN (Thibault et al., 2014). Oxycodone-induced analgesic effects were eliminated by a GABAB receptor antagonist, further suggesting that GABA is required for oxycodone to reduce CIPN symptoms. Lastly, injecting pro-inflammatory IL-17 into the spinal cord also decreased inhibitory signals that GABA produced, indicating that inflammation might be an upstream pathway for the inhibition of GABA (Luo et al., 2019).
Taken together, attenuation of inhibitory mechanisms could explain the observed increase in excitatory signals and increased brain activity observed in CIPN. Restoration of GABA levels specifically in the brain or non-specifically in the spinal cord and brain can reduce CIPN symptoms, and multiple analgesic drugs for CIPN control balance of inhibitory and excitatory transmission. Clinically, GABA and GABA analogs have been investigated as potential analgesics in CIPN and other conditions (Zaręba et al., 2020) because GABAergic neurons and receptors are involved in coordination of the perception and response to noxious stimuli (Enna and McCarson, 2006). However, GABAergic drugs are not commonly used as analgesics given their side effects such as muscle weakness, drowsiness, fatigue, upset stomach, and nausea (Enna and McCarson, 2006). Therefore, although it may not be desirable to introduce exogenous sources of GABA in the human brain to treat CIPN, non-invasive measurement of GABA in the brain (Mullins et al., 2014) might help direct the development and optimization of non-invasive interventions to maximize GABAergic signaling through endogenous mechanisms. Also, GABA levels in the brain could serve as a biomarker for CIPN or a mechanistic endpoint for clinical trials to treat or prevent CIPN.
Neuroinflammation
Neuroinflammation has been frequently proposed as an underlying peripheral mechanism of CIPN development (Wang et al., 2012; Starobova and Vetter, 2017; Ma et al., 2018; Brandolini et al., 201f9). Studies from our review suggest that the CNS is also in a pro-inflammatory state during CIPN, and that mitigating the increased neuroinflammation alleviates symptoms of CIPN. Indeed, oxaliplatin increases the levels of pro-inflammatory cytokines and their receptors within the dl-PAG, and decreases GABA levels within the dl-PAG (Xu et al., 2018). When Xu et al. injected pro-inflammatory cytokine receptor antagonists specifically to the dl-PAG to block inflammation, CIPN symptoms were reduced and GABA levels were restored.
Increases in both CIPN symptoms and pro-inflammatory markers in the spinal cord are observed following chemotherapeutic treatment. For instance, paclitaxel treatment increased the level of the pro-inflammatory cytokine IL-17 in the spinal cord (Luo et al., 2019). Intrathecal injection of IL-17 resulted in CIPN symptom development and decreased GABA signaling. IL-17 also increased neural excitation by increasing the amplitude of NMDAR excitatory post synaptic currents and the firing frequency of excitatory interneurons. Knockdown of the IL-17 receptor in the spinal cord eliminated all these effects, reducing CIPN, restoring GABA, and reducing hyperactivity (Luo et al., 2019). Increases in TNF-α, another pro-inflammatory cytokine, were also observed in the spinal cord following oxaliplatin treatment concomitant with CIPN symptoms. Moreover, experimentally blocking nuclear receptors REV-ERBs, upstream regulators of inflammatory gene transcription, in the spinal cord prevented LPS- and TNF-α-induced transcription of pro-inflammatory cytokines IL-1β and IL-6, and reduced CIPN symptoms (Morioka et al., 2019). Finally, neurotoxic agents such as paclitaxel increased pro-inflammatory cytokines and reduced levels of anti-inflammatory cytokines IL-4, IL-10, and IL-13. Restoration of IL-4 in the spinal cord decreased neuronal hyperactivity and attenuated CIPN symptoms (Nie et al., 2018).
Thus, several lines of evidence implicate neuroinflammation in the brain and spinal cord in both the development and maintenance of CIPN and suggest that anti-inflammatory treatments at the level of the CNS suppress CIPN. Chronic CIPN symptoms/maintenance may be mediated by the brain’s neuroinflammatory state based on similar findings in chronic pain (Ji et al., 2014; Ji et al., 2018). Indeed, new evidence suggests that glial activation may lead to long term alterations in neuronal excitability and maintain pain sensation even after the original insult has receded (Hansson, 2010; Ji et al., 2018). Reducing neuroinflammation may consequently help alleviate both acute and chronic CIPN. These observations raise the possibility that CIPN might be treated by interventions that reduce neuroinflammation, such as drugs (e.g., non-steroidal anti-inflammatory drugs shown helpful for diabetic neuropathy Cohen and Harris, 1987) or behavioral interventions (e.g., exercise Gleeson et al., 2011; Kleckner et al., 2018; Kleckner et al., 2019).
GPCR/MAPK
Signaling cascades downstream of binding to GPCRs are also implicated in CIPN (Borroto-Escuela et al., 2017). Paclitaxel CIPN symptoms were reduced using genetic knock out mice or antagonizing one or both kinin B1 and B2 GPCRs either systemically (intraperitoneally) or only centrally (ICV), suggesting a role of these GPCRs in the CNS in modulating CIPN (Costa et al., 2011). ICV administration of Orexin-A, a neuropeptide working through a GPCR, produced antinociceptive effects in mouse models of CIPN symptoms, whereas antagonizing the receptor blocked the orexin-induced antinociception (Toyama et al., 2017). Antinociceptive effects of morphine and oxycodone in oxaliplatin-treated rats (Kanabara et al., 2014a; Kanabara et al.,2014b) were blocked by ICV administration of either a Gi/o protein receptor inhibitor, or a GIRK1 channel blocker, which is downstream of the Gi/o protein. Elevated levels of phosphorylated PKC, MAPK, ERK, and SAP/JNK were also observed specifically within the thalamus and the PAG tissue homogenates following oxaliplatin treatment (Sanna et al., 2016; Norcini et al., 2009). These changes, along with CIPN symptoms, were reversed upon administration of a PKC inhibitor to the brain via ICV injection.
Similarly, other studies reported increased ERK phosphorylation in the spinal cord following oxaliplatin injection (Zhang et al., 2019). Furthermore, injection of an ERK inhibitor both reduced the level of phosphorylated ERK and reversed CIPN symptoms. No change in phosphorylation levels of other MAPKs, p38 or JNK was observed, which contrasts with the observed role of MAPK in the brain in CIPN (Sanna et al., 2016; Norcini et al., 2009). More work is necessary to elucidate the impact of chemotherapy on the kinetics of such signaling cascades and how these mechanisms can be exploited for treatment of CIPN.
There are several implications of these findings. First, GPCR/MAPK signaling in the brain appears to be involved in CIPN. Second, multiple drugs that reduce CIPN modulate MAPK signaling pathways. Because these signaling pathways are ultimately responsible for the transcription and synthesis of various proteins, it is difficult to discern the exact changes occurring (as is also the case with inflammation). However, GPCRs have become the focus of research attention for treating multiple other brain-mediated conditions such as anxiety and depression (Borroto-Escuela et al., 2017), and therefore may be promising targets of treatment for CIPN as well.
Other Findings
Several brain intervention studies did not fit into one of the above themes. Two lines of evidence support a role for the cholinergic system in the CNS in contributing to CIPN. First, oxaliplatin both increased the expression of the M2 acetylcholine receptors and decreased acetylcholine levels in the posterior insula whereas either activating the M2 receptor or restoring acetylcholine levels specifically in the posterior insula reversed CIPN symptoms (Ferrier et al., 2015). Second, inhibiting the nonselective nicotinic acetylcholine receptor and the α7 selective nicotinic acetylcholine receptor in the brain via ICV injection blocked the antinociceptive effects of CDP-Choline (Kanat et al., 2013). CDP-choline is an intermediate in the pathway for cell membrane phospholipid synthesis, and separates into its two components in the body, cytidine and choline. Choline is the primary precursor used by the brain to synthesize acetylcholine, suggesting that cholinergic pathways are involved in CIPN and its treatment. CDP-choline has also been shown to increase dopamine and norepinephrine levels in the CNS (Secades and Frontera, 1995; Secades and Lorenzo, 2006). These two monoamines, along with serotonin, have been shown to be involved in CIPN, as serotonin, norepinephrine, and dopamine reuptake inhibitors increased extracellular levels of their respective monoamines and each reversed a different combination of CIPN symptoms (Hache et al., 2015). Administration of a single triple monoamine reuptake inhibitor elevated the extracellular levels of all three monoamines, and completely reversed all CIPN symptoms. Similarly, systemic duloxetine (also a serotonin and norepinephrine reuptake inhibitor) reduced CIPN symptoms (Smith et al., 2013) consistent with Nagasaka et al. (2017). Third, ICV delivery of gabapentin, a voltage-gated Ca2+ channel inhibitor, decreased paclitaxel-induced mechanical hypersensitivity and pain aversiveness in a dose-dependent manner (Juarez-Salinas et al., 2018). Finally, injection of neuronal nitric oxide synthase into the lateral cerebral ventricle of paclitaxel-treated rats reversed CIPN symptoms through hyperbaric oxygen, and the antinociceptive effect of hyperbaric oxygen was eliminated with an inhibitor of neuronal nitric oxide synthase (Zhang et al., 2019). Taken together, these reports support diverse mechanisms of brain hyperactivity in CIPN and mechanisms to reduce that hyperactivity. These less commonly studied mechanisms suggest the presence of promising opportunities for future research.
Overall Discussion
Summary of findings (Figure 2). This is the first paper to summarize the literature on the role of the brain in CIPN. We reviewed five correlational studies of CIPN and brain imaging in humans and non-human primates (Table 2), 16 papers studying interventions to the brain that cause or reduce CIPN symptoms (Table 3), and eight papers using interventions to the spinal cord (Table 4) and we highlight four key themes. First, CIPN is associated with hyperactivity and hyperexcitability in several brain regions including the PAG, thalamus, ACC, S2, and insula, which makes sense as they are part of well-known circuitry related to sensation and perception including pain (Kleckner et al., 2017; Reddan and Wager, 2018). Second, CIPN is associated reduced GABAergic inhibition in the brain, thereby changing excitatory/inhibitory balance to create a molecular environment promoting neuronal hyperactivity. Moreover, activating GABA receptors or increasing GABA levels reduces symptoms of CIPN. Third, these brain regions exhibit a pro-inflammatory state, which is consistent with prior work indicating that oxaliplatin activates astrocytes in the ACC in mice (Masocha, 2015) and that neuroinflammation increases neural excitability (Leung and Cahill, 2010). Blocking key inflammatory pathways in the brain restores GABA levels, reduces neuronal excitability, and reduces CIPN. Fourth, GPCR and MAPK phosphorylation pathways are also implicated in CIPN, which lead to changes in transcription and neuroinflammation (and likely other changes). Experimentally manipulating the GPCR pathways to reduce PKC or MAPK phosphorylation in the brain reduces CIPN symptoms. Finally, studies suggest CIPN is related to monoamines (e.g., serotonin, norepinephrine, dopamine), oxidative stress, acetylcholine receptor expression, and ion channel expression (reduction in voltage-gated K+ and increase in voltage-gated Ca2+ channel activity).
FIGURE 2. Conceptual model for the role of the brain in CIPN based on the evidence reviewed herein. The red text indicates brain factors that cause or are correlated with CIPN. The blue text indicates brain interventions shown to treat or reduce CIPN via the experimental studies (first author provided in parentheses; all studies reviewed in Table 3). Lines ending in a circle indicate blocking or reducing the target whereas lines ending in an arrow indicate activating or increasing the target. The key brain regions studied and implicated in our review include the periaqueductal gray (PAG), thalamus, anterior cingulate cortex (ACC), secondary somatosensory cortex (S2), and insula.
Our review has the potential to shift the theoretical paradigm of CIPN as not exclusively a peripheral phenomenon and help focus more research attention on the brain. This shift can help advance preclinical and clinical research on CIPN to inform additional and more impactful studies of the brain in CIPN, which are urgently needed according to the 2017 National Cancer Institute Clinical Trials Planning Meeting on CIPN (Dorsey, Kleckner et al., 2019). This future research agenda will ultimately lead to a greater understanding of CIPN and more effective diagnostics, prophylactics, and treatments for CIPN. In the remaining paragraphs, we discuss potential mechanisms of how chemotherapy affects the brain, how the brain is involved in CIPN at the neural systems level, implications for the role of the brain in CIPN for preclinical research, clinical research, and clinical treatment of CIPN, the potential for a unified theory of the brain in multiple chemotherapy toxicities, and finally, we address the strengths and limitations of our review. We consider changes in the brain at various levels of analysis (e.g., molecular, cellular, systems/networks) for two reasons: (1) because most brain measures occur at the microscopic level in non-human animals yet at the macroscopic level in humans, and (2) to consider both reductionist and holistic approaches to relationships between neurobiology and subjective experience (i.e., symptoms) (Krakauer et al., 2017).
The possibility of direct and indirect effects of chemotherapy on the brain in CIPN. It is possible but unlikely that brain changes summarized here (e.g., hyperactivity) are caused by chemotherapy entering the brain. Indeed, the idea that chemotherapy accumulates in the human brain has been debated, and likely depends on the type of chemotherapy, the dose density, and other factors that may compromise the blood brain barrier (Branca et al., 2018). In rodents, although paclitaxel has been found in the brain after peripheral infusions (Cavaletti et al., 2000), cisplatin has only been found in the brain under extreme circumstances such as excessive chemotherapy dose (Screnci, McKeage et al., 2000), hypoxia, or lipopolysaccharide challenge (Minami et al., 1996a; Minami et al., 1996b; Minami et al., 1996c; Minami et al., 1998). There is relatively more evidence that the spinal cord accumulates neurotoxic chemotherapy, such as oxaliplatin found in the cerebrospinal fluid (Huang et al., 2016) and DRG in humans (Krarup-Hansen et al., 1999) and rodents (Screnci et al., 2000), perhaps because the DRG lack the protective blood brain barrier.
It appears more likely that brain changes seen in CIPN are caused by indirect effects of neurotoxic chemotherapy on the brain. Indeed, we hypothesize that the brain undergoes significant compensation due to altered afferent input including unusually excessive input from some sensory nerves and lack of input from others, as is the case with phantom limb pain (Makin and Flor, 2020). Brain compensation makes sense from a predictive coding perspective of the brain (Friston, 2018) (and related ideas such as active inference and the Bayesian brain hypothesis), which posits that perceptual experience is driven primarily by the brain’s predictions of a given moment of consciousness, and that prediction is merely tailored—not driven—by afferent sensory input. Note that predictive coding models of the brain contrast traditional stimulus-response models of the brain, in which perceptual experience is primarily driven by sensory input. In accord with a modern neuropsychological perspective of the mind (Barrett, 2017; Hutchinson and Barrett, 2019), we consider perception to include sights, sounds, feelings, emotions, thoughts, memories, and symptoms, including those of CIPN, as we have previously suggested (Kleckner et al., 2018). Therefore, neurotoxic chemotherapy might cause the brain’s circuitry for generating predictions (and thus perceptions) to undergo significant changes in neural coding to account for the chronically unexpected peripheral sensory input that occurs in CIPN. Changes in coding would likely require additional metabolic needs to brain regions involved in predictions, consistent with brain hyperactivity and hyperperfusion observed in this review. Indeed, the regions of the brain that are proposed to initiate predictions include the major hubs of the DMN such as the ACC (Barrett and Simmons, 2015), which are highly connected to sensory regions such as the insula, S2, thalamus, and PAG (Kleckner et al., 2017), which are all implicated in CIPN per our review herein. This hypothetical compensation in the brain might have implications for traditional perspectives of the role of the brain in pain, such as how neurotoxic chemotherapy might cause a reduction in descending inhibition of pain (e.g., according to Gate Control Theory Melzack and Wall, 1965). For completeness, these hypothetical changes in the brain would be concurrent with other effects of chemotherapy such as neuroinflammation (McLeary et al., 2019), which sensitizes neurons and causes hyperactivity (Vezzani and Viviani, 2015).
Preclinical research implications First and foremost, we need more studies testing brain interventions and brain mechanisms because this type of detailed work is unethical or impractical in humans. Indeed, chemotherapy is never delivered to humans in the absence of cancer and an impact of prior cancer cannot be excluded; thus, animal models uniquely allow us to learn about CIPN in the absence of cancer. Also, we should not assume that what we observe in the periphery or spinal cord in relation to CIPN also occurs in the brain, because the brain, the spinal cord, and peripheral nervous system differ in terms of their function, their biology, their accessibility by neurotoxic drugs, etc. Second, we need more studies of animals whose brains and CIPN more closely resemble that of humans (Hama et al., 2018), and the animal research should use measures and analytical methods more similar to those used in human studies. In terms of measures, to our knowledge there are only two studies in rodents using structural, functional, or diffusion tensor MRI (Ferris et al., 2019; Alkislar et al., 2020), which are measures commonly used in humans. In terms of analytical methods, many human brain imaging studies assess correlations between brain measures or their changes (e.g., activity, perfusion) and CIPN measures or their changes, but this type of analysis is only rarely conducted in the preclinical studies we identified. Preclinical studies typically randomize animals to chemotherapy vs. vehicle (which is good), demonstrate that CIPN is present in the chemotherapy group (which is also good), and assess brain differences between CIPN and non-CIPN groups (which is insufficient). The latter analysis is insufficient because brain differences may not be related to CIPN but rather reflect brain differences attributable to other chemotherapy effects (e.g., chemotherapy-induced cognitive impairment, changes in food consumption, hydration status, voluntary physical activity, social behavior, etc.). Next, researchers should recognize that possible CIPN interventions can affect the brain (i.e., CNS penetrant vs. peripherally restricted), even if the drugs are delivered systemically (e.g., Slivicki et al., 2018; Slivicki et al., 2019). Finally, considering the role of the brain could provide insight into the autonomic components of CIPN (Verstappen et al., 2003; Nahman-Averbuch et al., 2014). For example, peripheral neuropathy often involves dysfunction in the reflexive wrinkling of glabrous skin during water immersion (Ng et al., 2013; Wilder-Smith, 2015), which appears to be related to central autonomic function (Win et al., 2010), which is mediated by the brain (Sklerov et al., 2019).
Clinical research implications: brain mechanisms, brain biomarkers, and brain-based interventions First, regarding brain mechanisms, out of the four common themes we identified, only one of those has been investigated in humans (hyperactivity), and the remaining themes should be studied to gain a better understanding of the role of the human brain in CIPN. Second, knowledge of those brain mechanisms can inform brain biomarkers of CIPN, for which there are currently none. If a highly accurate and reliable biomarker for CIPN is identified, it can help increase sensitivity and reduce bias in clinical trials of CIPN treatments, and it might also serve as a risk factor for predicting which patients will experience the worst CIPN or experience the best recovery of CIPN symptoms after completion of chemotherapy. In addition, the biomarker might be related to the brain but could be measured peripherally, such as a recent study finding that serum levels of brain-derived neurotrophic growth factor predicted CIPN and overall survival in 91 patients with multiple myeloma receiving bortezomib and/or thalidomide (Szudy-Szczyrek et al., 2020). Third, an impressive array of brain-based interventions warrant testing for their ability to modulate brain mechanisms involved in CIPN. Those interventions include neuromodulation (rTMS, tDCS, spinal cord stimulation), neurofeedback (fMRI, EEG per Prinsloo et al. in Table 2), and pharmacological, behavioral, and peripheral interventions that also affect the brain such as neurotransmitter modulators (e.g., duloxetine, bupropion), peripheral nerve stimulation (transcutaneous electrical nerve stimulation, scrambler therapy, vagus nerve stimulation), meditation, exercise, and cognitive behavioral therapy or combination therapies to amplify an intervention’s effect on the brain (e.g., tDCS during exercise, duloxetine plus exercise). In future studies of those interventions, it is important to include brain measures to help elucidate brain mechanisms of treatment or potential subgroup effects (responders vs. non-responders).
Clinical implications Additional knowledge of the role of the brain in CIPN can ultimately inform better CIPN diagnostics, biomarkers, and treatments. Brain imaging might help inform a diagnosis of CIPN or identify CIPN sub-types, which has been successful in other brain-mediated conditions such as depression (Sanacora et al., 2004; Takamura and Hanakawa, 2017; Tokuda et al., 2018). These biomarkers could help track toxicity during chemotherapy to help patients and medical oncologists weigh the risk/benefit ratio and decisions of chemotherapy dose vs. risks of long-term CIPN toxicity and cancer treatment effectiveness. The biomarkers could also help track response to interventions to reduce CIPN to determine that they are working via the expected mechanism and to select the proper dose of an intervention (e.g., amount of drug, intensity of neurostimulation or neurofeedback, amount or type of exercise).
A unified brain-based theory could explain multiple chemotherapy-induced toxicities including CIPN, fatigue, distress, nausea, and cognitive impairment. This idea leverages modern neuroscientific theories that emotions and other mental states are derived from interactions among a finite set of brain processes (Barrett, 2017; Kleckner et al., 2017; Barrett and Satpute, 2019; Hutchinson and Barrett, 2019). One of the most important brain processes is interoception (Craig, 2002; Khalsa et al., 2018), the processing of bodily sensations. In our prior work, we delineated an interoceptive brain system, which includes the insula, ACC, somatosensory cortex, thalamus, and PAG (all implicated in CIPN), as well as other regions largely delineated by a DMN-like network and a sensory-oriented network (Kleckner et al., 2017). Interoception likely plays a role in multiple chemotherapy toxicities because so many chemotherapy toxicities are strongly embodied with somatic symptoms. For example, fatigue is related to rationing energy resources (i.e., allostasis, which is intimately linked to interoception (Kleckner, Zhang et al., 2017)); fatigue has also been associated with CIPN in multiple studies (e.g., (Mols et al., 2013; Eckhoff et al., 2015; Beijers et al., 2016; Bonhof et al., 2019)). Distress, including anxiety and depression, is often experienced somatically in the heart, lungs, and gut, and distress and emotional processing are strongly dependent upon interoception (Paulus and Stein, 2010; Kleckner, Zhang et al., 2017). In addition, distress has been associated with CIPN (Bao et al., 2016; Toma et al., 2017; Lee et al., 2018; Bonhof et al., 2019); in fact, a recent study in 471 survivors of colorectal cancer found that symptoms of distress (anxiety, depression) mediate the effects of CIPN on fatigue (Bonhof, van de Poll-Franse et al., 2019). Nausea is based on predictions on the state of the gut and relies heavily on interoception (Wickham, 2020), and has been associated with CIPN (Mols et al., 2013; Ezendam et al., 2014). Finally, cognitive impairment includes memory components, the encoding of which includes bodily sensations, and thus interoception (Terasawa and Umeda, 2017). Cognitive impairment has been associated with CIPN in rodents (Fardell et al., 2015), but research in humans has been limited. There may be multiple underlying mechanisms contributing to a unified account of the role of the brain in chemotherapy toxicities (e.g., neuroinflammation Vichaya et al., 2015). However, because these ideas are relatively new and understudied, additional studies need to be designed to test the possibility and utility of a unified brain-based theory of multiple chemotherapy toxicities.
If our hypothesis is false, and the brain does not play a prominent or causal role in the development and treatment of CIPN, then there are alternative implications for future work. First, CIPN interventions that affect the brain (e.g., duloxetine) could merely mask symptoms of CIPN rather than treating factors that are part of the pathophysiological mechanism per se. Second, it suggests that researchers should continue to focus on mechanisms and treatments for peripheral damage to stop CIPN at its peripheral source. However, the lack of successful treatments for CIPN thus far despite significant research suggests that researchers should include more work with animal models that better translate to CIPN in humans (e.g., macaques Hama et al., 2018).
Strengths of this review This is the first review to summarize evidence regarding the contribution of the brain to CIPN and to summarize implications for research and treatment of CIPN. This review is also very timely given that a recent meeting of CIPN experts at the National Cancer Institute stressed the urgency and importance of developing new theoretical frameworks to understand CIPN (Dorsey et al., 2019). Second, our work is innovative in that our synthesis of results leverages modern neuroscience perspectives on mental states (e.g., the role of interoception and predictive coding). This novel theoretical framework of CIPN supports an innovative set of hypotheses regarding the role of the brain in CIPN and perhaps other chemotherapy toxicities. This framework will advance future research and ultimately clinical treatments for patients receiving chemotherapy. Third, multiple papers from different independent research groups support our hypothesis that the brain plays a prominent role in CIPN. In fact, these results are remarkably consistent with one another in terms identified themes, and there were multiple partially overlapping consistencies (e.g., activating the GABA receptor reduced CIPN whether by introducing a GABA-R agonist, increasing GABA levels, or blocking inflammation pathways to increase GABA).
Limitations of this review Due to heterogeneity in methods such as chemotherapy type, chemotherapy dosing schedule, brain measures, brain interventions, and CIPN assessments (e.g., cold allodynia, mechanical allodynia, mechanical hypersensitivity, and the various tests thereof), the emerging literature in this area reflects only a small number of papers supporting each theme. Second, our review does not include all possible explanations on the role of the brain in CIPN and there are likely other factors involved that simply have not been studied yet. Moreover, some of the brain-based interventions might also affect other regions of the brain or body, and perhaps systemically, or vice versa (e.g., if the delivered drug goes from the brain to the periphery, or indirect effects of a reduction in neuroinflammation reducing peripheral inflammation). Third, all the evidence suggesting that the brain plays a prominent or causal role in CIPN is based in non-human animals, and these methods are unethical in humans. However, even given these limitations, our review is important because it highlights gaps in the literature and opportunities for future research to further test the contributing role of brain mechanisms to CIPN.
Conclusion The vast majority of research on CIPN has focused on peripheral nerve damage but has yet to produce significant advances in the prevention and treatment of CIPN despite nearly 100 clinical trials for CIPN (Hershman et al., 2014; Loprinzi et al., 2020). Herein, we investigated the hypothesis that the brain plays a prominent or even causal role in CIPN by reviewing the literature on experimental manipulations of the brain to see its effect on CIPN in non-human animals. Our review implicated four common themes related to the role of the brain in CIPN, with brain hyperactivity being a key feature of the pathology of CIPN. We identified specific implications for preclinical research, clinical research, and clinical diagnosis, prevention, and treatment of CIPN that leverages knowledge of the role of the brain in CIPN. We also set the stage for a powerful unified brain-based theoretical framework for multiple chemotherapy toxicities, which is the first theory of its kind to our knowledge. Our review is the first to investigate the role of the brain in CIPN and it paves the way for more brain-based research, more advanced and specific theories on the role of the brain in CIPN, and clinical applications to prevent and treat CIPN to ultimately reduce the burden of chemotherapy on patients with cancer.
Author Contributions
IK conceptualized the review and provided oversight of the project. MO and IK conducted the literature review and led the writing of the manuscript. All other authors provided input on multiple drafts of the article. All authors approved the final article before submission.
Funding
The authors acknowledge funding from the National Institutes of Health, including K07CA221931 to IRK, T32102618 to support EB, CA200417 and DA041229 to AGH, and UG1CA189961.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgments
The authors would also like to thank Dr. Amber Kleckner for editorial input.
Footnotes
1To easily find papers in the alphabetically sorted tables, we refer to each paper by the last name of the first author.
2The Prinsloo paper used a waitlist control which cannot account for non-specific effects of neurofeedback, as opposed to a sham neurofeedback procedure.
References
Alkislar, I., Miller, A. R., Hohmann, A. G., Sadaka, A., Cai, X., Kulkarni, P., et al. (2020). Inhaled Cannabis Suppresses Chemotherapy-Induced Neuropathic Nociception by Decoupling the Raphe Nucleus: a Functional Imaging Study in Rats. Biol. Psych. Cognit. Neurosci. Neuroimag. 11, 343. doi:10.1016/j.bpsc.2020.11.015
Aoki, M., Kurauchi, Y., Mori, A., Nakahara, T., Sakamoto, K., and Ishii, K. (2014). Comparison of the Effects of Single Doses of Elcatonin and Pregabalin on Oxaliplatin-Induced Cold and Mechanical Allodynia in Rats. Biol. Pharm. Bull. 37 (2), 322–326. doi:10.1248/bpb.b13-00735
Argyriou, A. A., Cavaletti, G., Briani, C., Velasco, R., Bruna, J., Campagnolo, M., et al. (2013). Clinical Pattern and Associations of Oxaliplatin Acute Neurotoxicity. Cancer 119 (2), 438–444. doi:10.1002/cncr.27732
Bao, T., Basal, C., Seluzicki, C., Li, S. Q., Seidman, A. D., and Mao, J. J. (2016). Long-term Chemotherapy-Induced Peripheral Neuropathy Among Breast Cancer Survivors: Prevalence, Risk Factors, and Fall Risk. Breast Cancer Res. Treat. 159 (2), 327–333. doi:10.1007/s10549-016-3939-0
Barrett, L. F., and Satpute, A. B. (2019). Historical Pitfalls and New Directions in the Neuroscience of Emotion. Neurosci. Lett. 693, 9–18. doi:10.1016/j.neulet.2017.07.045
Barrett, L. F., and Simmons, W. K. (2015). Interoceptive Predictions in the Brain. Nat. Rev. Neurosci. 16 (7), 419–429. doi:10.1038/nrn3950
Barrett, L. F. (2017). The Theory of Constructed Emotion: an Active Inference Account of Interoception and Categorization. Soc. Cogn. affective Neurosci. 12 (1), 1–23. doi:10.1093/scan/nsx060
Beijers, A. J. M., Vreugdenhil, G., Oerlemans, S., Eurelings, M., Minnema, M. C., Eeltink, C. M., et al. (2016). Chemotherapy-induced Neuropathy in Multiple Myeloma: Influence on Quality of Life and Development of a Questionnaire to Compose Common Toxicity Criteria Grading for Use in Daily Clinical Practice. Support Care Cancer 24 (6), 2411–2420. doi:10.1007/s00520-015-3032-y
Binshtok, A. M., Wang, H., Zimmermann, K., Amaya, F., Vardeh, D., Shi, L., et al. (2008). Nociceptors Are Interleukin-1 Sensors. J. Neurosci. 28 (52), 14062–14073. doi:10.1523/jneurosci.3795-08.2008
Boland, E. G., Selvarajah, D., Hunter, M., Ezaydi, Y., Tesfaye, S., Ahmedzai, S. H., et al. (2014). Central Pain Processing in Chronic Chemotherapy-Induced Peripheral Neuropathy: a Functional Magnetic Resonance Imaging Study. PLoS One 9 (5), e96474. doi:10.1371/journal.pone.0096474
Bonhof, C. S., Poll‐Franse, L. V., Vissers, P. A. J., Wasowicz, D. K., Wegdam, J. A., Révész, D., et al. (2019). Anxiety and Depression Mediate the Association between Chemotherapy‐induced Peripheral Neuropathy and Fatigue: Results from the Population‐based PROFILES Registry. Psycho‐Oncology 28 (9), 1926–1933. doi:10.1002/pon.5176
Borroto-Escuela, D. O., Carlsson, J., Ambrogini, P., Narváez, M., Wydra, K., Tarakanov, A. O., et al. (2017). Understanding the Role of GPCR Heteroreceptor Complexes in Modulating the Brain Networks in Health and Disease. Front. Cell. Neurosci. 11, 37. doi:10.3389/fncel.2017.00037
Branca, J. J. V., Maresca, M., Morucci, G., Becatti, M., Paternostro, F., Gulisano, M., et al. (2018). Oxaliplatin-induced Blood Brain Barrier Loosening: a New point of View on Chemotherapy-Induced Neurotoxicity. Oncotarget 9 (34), 23426–23438. doi:10.18632/oncotarget.25193
Brandolini, L., d'Angelo, M., Antonosante, A., Allegretti, M., and Cimini, A. (2019). Chemokine Signaling in Chemotherapy-Induced Neuropathic Pain. Int. J. Mol. Sci. 20 (12), 112. doi:10.3390/ijms20122904
Bráz, J. M., Wang, X., Guan, Z., and Basbaum, J. L. A. I. (2015). Transplant-mediated Enhancement of Spinal Cord GABAergic Inhibition Reverses Paclitaxel-Induced Mechanical and Heat Hypersensitivity. Pain 156 (6), 1084–1091. doi:10.1097/j.pain.0000000000000152
Byrd‐Leifer, C. A., Block, E. F., Takeda, K., Akira, S., and Ding, A. (2001). The Role of MyD88 and TLR4 in the LPS‐mimetic Activity of Taxol. Eur. J. Immunol. 31 (8), 2448–2457.
Castellanos, A., Pujol‐Coma, A., Andres‐Bilbe, A., Negm, A., Callejo, G., Soto, D., et al. (2020). TRESK Background K + Channel Deletion Selectively Uncovers Enhanced Mechanical and Cold Sensitivity. J. Physiol. 598 (5), 1017–1038. doi:10.1113/jp279203
Cavaletti, G., Cavalletti, E., Oggioni, N., Sottani, C., Minoia, C., D'Incalci, M., et al. (2000). Distribution of Paclitaxel within the Nervous System of the Rat after Repeated Intravenous Administration. Neurotoxicology 21 (3), 389–393.
Cavaletti, G., Alberti, P., Frigeni, B., Piatti, M., and Susani, E. (2011). Chemotherapy-Induced Neuropathy. Curr. Treat. Options. Neurol. 13 (2), 180–190. doi:10.1007/s11940-010-0108-3
Chan, A., Hertz, D. L., Morales, M., Adams, E. J., Gordon, S., Tan, C. J., et al. (2019). Biological Predictors of Chemotherapy-Induced Peripheral Neuropathy (CIPN): MASCC Neurological Complications Working Group Overview. Support. Care Cancer 27, 1–9. doi:10.1007/s00520-019-04987-8
Chan, C. W., Cheng, H., Au, S. K., Leung, K. T., Li, Y. C., Wong, K. H., et al. (2018). Living with Chemotherapy-Induced Peripheral Neuropathy: Uncovering the Symptom Experience and Self-Management of Neuropathic Symptoms Among Cancer Survivors. Eur. J. Oncol. Nurs. 36, 135–141. doi:10.1016/j.ejon.2018.09.003
Chen, Y., Yang, C., and Wang, Z. J. (2011). Proteinase-activated Receptor 2 Sensitizes Transient Receptor Potential Vanilloid 1, Transient Receptor Potential Vanilloid 4, and Transient Receptor Potential Ankyrin 1 in Paclitaxel-Induced Neuropathic Pain. Neuroscience 193, 440–451. doi:10.1016/j.neuroscience.2011.06.085
Cohen, K. L., and Harris, S. (1987). Efficacy and Safety of Nonsteroidal Anti-inflammatory Drugs in the Therapy of Diabetic Neuropathy. Arch. Intern. Med. 147 (8), 1442–1444. doi:10.1001/archinte.147.8.1442
Costa, R., Motta, E. M., Dutra, R. C., Manjavachi, M. N., Bento, A. F., Malinsky, F. R., et al. (2011). Anti‐nociceptive Effect of Kinin B 1 and B 2 Receptor Antagonists on Peripheral Neuropathy Induced by Paclitaxel in Mice. Br. J. Pharmacol. 164 (2b), 681–693. doi:10.1111/j.1476-5381.2011.01408.x
Craig, A. D. (2002). How Do You Feel? Interoception: the Sense of the Physiological Condition of the Body. Nat. Rev. Neurosci. 3 (8), 655–666. doi:10.1038/nrn894
De Andrade, D. C., Jacobsen Teixeira, M., Galhardoni, R., Ferreira, K. S. L., Braz Mileno, P., Scisci, N., et al. (2017). Pregabalin for the Prevention of Oxaliplatin‐Induced Painful Neuropathy: A Randomized, Double‐Blind Trial. Oncol. 22 (10), 1154. doi:10.1634/theoncologist.2017-0235
De Grandis, D. (2007). Acetyl-l-Carnitine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy. CNS Drugs 21 (Suppl. 1), 39–43. doi:10.2165/00023210-200721001-00006
Descoeur, J., Pereira, V., Pizzoccaro, A., Francois, A., Ling, B., Maffre, V., et al. (2011). Oxaliplatin‐induced Cold Hypersensitivity Is Due to Remodelling of Ion Channel Expression in Nociceptors. EMBO Mol. Med. 3 (5), 266–278. doi:10.1002/emmm.201100134
Dorsey, S. G., Kleckner, I. R., Barton, D., Mustian, K., O'Mara, A., St Germain, D., et al. (2019). NCI Clinical Trials Planning Meeting for Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy. J. Natl. Cancer Inst. 111, 531–537. doi:10.1158/1078-0432.CCR-18-2152
Dougherty, P. M. (2016). Is Chemotherapy-Induced Peripheral Neuropathy More Than Just a Peripheral Nervous System Disorder? Anesthesiology 124 (5), 992–993. doi:10.1097/aln.0000000000001085
Eckhoff, L., Knoop, A., Jensen, M., and Ewertz, M. (2015). Persistence of Docetaxel-Induced Neuropathy and Impact on Quality of Life Among Breast Cancer Survivors. Eur. J. Cancer 51 (3), 292–300. doi:10.1016/j.ejca.2014.11.024
Enna, S. J., and McCarson, K. E. (2006). The Role of GABA in the Mediation and Perception of Pain. Adv. Pharmacol. 54, 1–27. doi:10.1016/s1054-3589(06)54001-3
Ezendam, N. P. M., Pijlman, B., Bhugwandass, C., Pruijt, J. F. M., Mols, F., Vos, M. C., et al. (2014). Chemotherapy-induced Peripheral Neuropathy and its Impact on Health-Related Quality of Life Among Ovarian Cancer Survivors: Results from the Population-Based PROFILES Registry. Gynecol. Oncol. 135 (3), 510–517. doi:10.1016/j.ygyno.2014.09.016
Fardell, J. E., Vardy, J., Monds, L. A., and Johnston, I. N. (2015). The Long-Term Impact of Oxaliplatin Chemotherapy on Rodent Cognition and Peripheral Neuropathy. Behav. Brain Res. 291, 80–88. doi:10.1016/j.bbr.2015.04.038
Ferrier, J., Bayet-Robert, M., Dalmann, R., El Guerrab, A., Aissouni, Y., Graveron-Demilly, D., et al. (2015). Cholinergic Neurotransmission in the Posterior Insular Cortex Is Altered in Preclinical Models of Neuropathic Pain: Key Role of Muscarinic M2 Receptors in Donepezil-Induced Antinociception. J. Neurosci. 35 (50), 16418–16430. doi:10.1523/jneurosci.1537-15.2015
Ferris, C. F., Nodine, S., Pottala, T., Cai, X., Knox, T. M., Fofana, F. H., et al. (2019). Alterations in Brain Neurocircuitry Following Treatment with the Chemotherapeutic Agent Paclitaxel in Rats. Neurobiol. Pain 6, 100034. doi:10.1016/j.ynpai.2019.100034
Fidanboylu, M., Griffiths, L. A., and Flatters, S. J. (2011). Global Inhibition of Reactive Oxygen Species (ROS) Inhibits Paclitaxel-Induced Painful Peripheral. PLoS ONE 6, e25212. doi:10.1371/journal.pone.0025212
Flatters, S. J., and Bennett, G. J. (2004). Ethosuximide Reverses Paclitaxel-And Vincristine-Induced Painful Peripheral Neuropathy. Pain 109 (1-2), 150–161. doi:10.1016/j.pain.2004.01.029
Flatters, S. J. L., and Bennett, G. J. (2006). Studies of Peripheral Sensory Nerves in Paclitaxel-Induced Painful Peripheral Neuropathy: Evidence for Mitochondrial Dysfunction. Pain 122 (3), 245–257. doi:10.1016/j.pain.2006.01.037
Flatters, S. J. L., Dougherty, P. M., and Colvin, L. A. (2017). Clinical and Preclinical Perspectives on Chemotherapy-Induced Peripheral Neuropathy (CIPN): a Narrative Review. Br. J. Anaesth. 119 (4), 737–749. doi:10.1093/bja/aex229
Friston, K. (2018). Does Predictive Coding Have a Future?. Nat. Neurosci. 21 (8), 1019–1021. doi:10.1038/s41593-018-0200-7
Gamper, N., and Ooi, L. (2015). Redox and Nitric Oxide-Mediated Regulation of Sensory Neuron Ion Channel Function. Antioxid. Redox Signaling 22 (6), 486–504. doi:10.1089/ars.2014.5884
Gauchan, P., Andoh, T., Ikeda, K., Fujita, M., Sasaki, A., Kato, A., et al. (2009). Mechanical Allodynia Induced by Paclitaxel, Oxaliplatin and Vincristine: Different Effectiveness of Gabapentin and Different Expression of Voltage-dependent Calcium Channel .ALPHA.2.DELTA.-1 Subunit. Biol. Pharm. Bull. 32 (4), 732–734. doi:10.1248/bpb.32.732
Gleeson, M., Bishop, N. C., Stensel, D. J., Lindley, M. R., Mastana, S. S., and Nimmo, M. A. (2011). The Anti-inflammatory Effects of Exercise: Mechanisms and Implications for the Prevention and Treatment of Disease. Nat. Rev. Immunol. 11 (9), 607–615. doi:10.1038/nri3041
Grolleau, F., Gamelin, L., Boisdron-Celle, M., Lapied, B., Pelhate, M., and Gamelin, E. (2001). A Possible Explanation for a Neurotoxic Effect of the Anticancer Agent Oxaliplatin on Neuronal Voltage-Gated Sodium Channels. J. Neurophysiol. 85 (5), 2293–2297. doi:10.1152/jn.2001.85.5.2293
Hache, G., Guiard, B. P., Nguyen, T. H., Quesseveur, G., Gardier, A. M., Peters, D., et al. (2015). Antinociceptive Activity of the New Triple Reuptake Inhibitor NS 18283 in a Mouse Model of Chemotherapy‐induced Neuropathic Pain. Ejp 19 (3), 322–333. doi:10.1002/ejp.550
Hama, A., Natsume, T., Ogawa, S. y., Higo, N., Hayashi, I., and Takamatsu, H. (2018). Gaps in Understanding Mechanism and Lack of Treatments: Potential Use of a Nonhuman Primate Model of Oxaliplatin-Induced Neuropathic Pain. Pain Res. Manag. 11, 21. doi:10.1155/2018/1630709
Hansson, E. (2010). Long-term Pain, Neuroinflammation and Glial Activation. Scand. J. pain 1 (2), 67–72. doi:10.1016/j.sjpain.2010.01.002
Hara, T., Chiba, T., Abe, K., Makabe, A., Ikeno, S., Kawakami, K., et al. (2013). Effect of Paclitaxel on Transient Receptor Potential Vanilloid 1 in Rat Dorsal Root Ganglion. PAIN 154 (6), 882–889. doi:10.1016/j.pain.2013.02.023
Hershman, D. L., Lacchetti, C., Dworkin, R. H., Lavoie Smith, E. M., Bleeker, J., Cavaletti, G., et al. (2014). Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. Jco 32 (18), 1941–1967. doi:10.1200/jco.2013.54.0914
Hershman, D. L., Unger, J. M., Crew, K. D., Minasian, L. M., Awad, D., Moinpour, C. M., et al. (2013). Randomized Double-Blind Placebo-Controlled Trial of Acetyl-l-Carnitine for the Prevention of Taxane-Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy. Jco 31 (20), 2627–2633. doi:10.1200/jco.2012.44.8738
Hu, L.-Y., Mi, W.-L., Wu, G.-C., Wang, Y.-Q., and Mao-Ying, Q.-L. (2019). Prevention and Treatment for Chemotherapy-Induced Peripheral Neuropathy: Therapies Based on CIPN Mechanisms. Cn 17 (2), 184–196. doi:10.2174/1570159x15666170915143217
Huang, Z.-Z., Li, D., Ou-Yang, H.-D., Liu, C.-C., Liu, X.-G., Ma, C., et al. (2016). Cerebrospinal Fluid Oxaliplatin Contributes to the Acute Pain Induced by Systemic Administration of Oxaliplatin. Anesthesiology: J. Am. Soc. Anesthesiologists 124 (5), 1109–1121. doi:10.1097/aln.0000000000001084
Hutchinson, J. B., and Barrett, L. F. (2019). The Power of Predictions: An Emerging Paradigm for Psychological Research. Curr. Dir. Psychol. Sci. 28 (3), 280–291. doi:10.1177/0963721419831992
Janes, K., Doyle, T., Bryant, L., Esposito, E., Cuzzocrea, S., Ryerse, J., et al. (2013). Bioenergetic Deficits in Peripheral Nerve Sensory Axons during Chemotherapy-Induced Neuropathic Pain Resulting from Peroxynitrite-Mediated post-translational Nitration of Mitochondrial Superoxide Dismutase. PAIN 154 (11), 2432–2440. doi:10.1016/j.pain.2013.07.032
Ji, R.-R., Nackley, A., Huh, Y., Terrando, N., and Maixner, W. (2018). Neuroinflammation and central Sensitization in Chronic and Widespread Pain. AnesthesiologyThe J. Am. Soc. Anesthesiologists 129 (2), 343–366. doi:10.1097/aln.0000000000002130
Ji, R.-R., Xu, Z.-Z., and Gao, Y.-J. (2014). Emerging Targets in Neuroinflammation-Driven Chronic Pain. Nat. Rev. Drug Discov. 13 (7), 533–548. doi:10.1038/nrd4334
Juarez-Salinas, D. L., Braz, J. M., Hamel, K. A., and Basbaum, A. I. (2018). Pain Relief by Supraspinal Gabapentin Requires Descending Noradrenergic Inhibitory Controls. Pr9 3 (4), e659. doi:10.1097/pr9.0000000000000659
Kanat, O., Kanat, D., Ozboluk, D. H. Y., and Gurun, M. S. (2013). Preclinical Evidence for the Antihyperalgesic Activity of CDP-Choline in Oxaliplatin-Induced Neuropathic Pain. J. BUON 18 (4), 1012–1018.
Kanbara, T., Nakamura, A., Shibasaki, M., Mori, T., Suzuki, T., Sakaguchi, G., et al. (2014a). Morphine and Oxycodone, but Not Fentanyl, Exhibit Antinociceptive Effects Mediated by G-Protein Inwardly Rectifying Potassium (GIRK) Channels in an Oxaliplatin-Induced Neuropathy Rat Model. Neurosci. Lett. 580, 119–124. doi:10.1016/j.neulet.2014.08.005
Kanbara, T., Nakamura, A., Takasu, K., Ogawa, K., Shibasaki, M., Mori, T., et al. (2014b). The Contribution of Gi/o Protein to Opioid Antinociception in an Oxaliplatin-Induced Neuropathy Rat Model. J. Pharmacol. Sci. 126 (3), 264–273. doi:10.1254/jphs.14133fp
Khalsa, S. S., Adolphs, R., Cameron, O. G., Critchley, H. D., Davenport, P. W., Feinstein, J. S., et al. (2018). Interoception and Mental Health: A Roadmap. Biol. Psychiatry Cogn. Neurosci. Neuroimaging 3 (6), 501–513. doi:10.1016/j.bpsc.2017.12.004
Kim, H. K., Zhang, Y. P., Gwak, Y. S., and Abdi, S. (2010). Phenyl N -Tert-Butylnitrone, a Free Radical Scavenger, Reduces Mechanical Allodynia in Chemotherapy-Induced Neuropathic Pain in Rats. Anesthesiology: J. Am. Soc. Anesthesiologists 112 (2), 432–439. doi:10.1097/aln.0b013e3181ca31bd
Kleckner, I. R., Kamen, C., Cole, C., Fung, C., Heckler, C. E., Guido, J. J., et al. (2019). Effects of Exercise on Inflammation in Patients Receivingchemotherapy: a Nationwide NCORP Randomized Clinical Trial. Support. Care Cancer 27, 4615–4625. doi:10.1007/s00520-019-04772-7
Kleckner, I. R., Kamen, C., Gewandter, J. S., Mohile, N. A., Heckler, C. E., Culakova, E., et al. (2018). Effects of Exercise during Chemotherapy on Chemotherapy-Induced Peripheral Neuropathy: a Multicenter, Randomized Controlled Trial. Support Care Cancer 26 (4), 1019–1028. doi:10.1007/s00520-017-4013-0
Kleckner, I. R., Park, S. B., Streckmann, F., Wiskemann, J., Hardy, S., and Mohile, N. A. (2021a). “Clinical and Practical Recommendations in the Use of Exercise, Physical Therapy, and Occupational Therapy for Chemotherapy-Induced Peripheral Neuropathy,” in Diagnosis, Management and Emerging Strategies for Chemotherapy Induced Neuropathy. Editors M. B. Lustberg, and C. L. Loprinzi (Berlin: Springer).
Kleckner, I. R., Park, S. B., Streckmann, F., Wiskemann, J., Hardy, S., and Mohile, N. A. (2021b). “Systematic Review of Exercise for Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy,” in Diagnosis, Management and Emerging Strategies for Chemotherapy Induced Neuropathy. Editors M. B. Lustberg, and C. L. Loprinzi (Berlin: Springer).
Kleckner, I. R., and Quigley, K. S. (2015). “An Approach to Mapping the Neurophysiological State of the Body to Affective Experience,” in The Psychological Construction of Emotion. Editors L. F. Barrett, and J. Russell (New York: Guilford).
Kleckner, I. R., Zhang, J., Touroutoglou, A., Chanes, L., Xia, C., Simmons, W. K., et al. (2017). Evidence for a Large-Scale Brain System Supporting Allostasis and Interoception in Humans. Nat. Hum. Behav. 1, 22. doi:10.1038/s41562-017-0069
Krakauer, J. W., Ghazanfar, A. A., Gomez-Marin, A., MacIver, M. A., and Poeppel, D. (2017). Neuroscience Needs Behavior: Correcting a Reductionist Bias. Neuron 93 (3), 480–490. doi:10.1016/j.neuron.2016.12.041
Krarup-Hansen, A., Rietz, B., Krarup, C., Heydorn, K., Rørth, M. H., and Schmalbruch, H. (1999). Histology and Platinum Content of Sensory Ganglia and Sural Nerves in Patients Treated with Cisplatin and Carboplatin: an Autopsy Study. Neuropathol. Appl. Neurobiol. 25 (1), 29–40. doi:10.1046/j.1365-2990.1999.00160.x
Lee, K.-M., Jung, D., Hwang, H., Son, K.-L., Kim, T.-Y., Im, S.-A., et al. (2018). Pre-treatment Anxiety Is Associated with Persistent Chemotherapy-Induced Peripheral Neuropathy in Women Treated with Neoadjuvant Chemotherapy for Breast Cancer. J. psychosomatic Res. 108, 14–19. doi:10.1016/j.jpsychores.2018.02.012
Leung, L., and Cahill, C. M. (2010). TNF-α and Neuropathic Pain-A Review. J. neuroinflammation 7 (1), 1–11. doi:10.1186/1742-2094-7-27
Li, W., Qin, W., Liu, H., Fan, L., Wang, J., Jiang, T., et al. (2013). Subregions of the Human superior Frontal Gyrus and Their Connections. Neuroimage 78, 46–58. doi:10.1016/j.neuroimage.2013.04.011
Li, Y., Zhang, H., Kosturakis, A. K., Cassidy, R. M., Zhang, H., Kennamer-Chapman, R. M., et al. (2015). MAPK Signaling Downstream to TLR4 Contributes to Paclitaxel-Induced Peripheral Neuropathy. Brain Behav. Immun. 49, 255–266. doi:10.1016/j.bbi.2015.06.003
Li, Y., Zhang, H., Zhang, H., Kosturakis, A. K., Jawad, A. B., and Dougherty, P. M. (2014). Toll-like Receptor 4 Signaling Contributes to Paclitaxel-Induced Peripheral Neuropathy. The J. Pain 15 (7), 712–725. doi:10.1016/j.jpain.2014.04.001
Loprinzi, C. L., Lacchetti, C., Bleeker, J., Cavaletti, G., Chauhan, C., Hertz, D. L., et al. (2020). Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J. Clin. Oncol. 38, 3325–3348. doi:10.1200/JCO.20.01399
Luo, H., Liu, H.-Z., Zhang, W.-W., Matsuda, M., Lv, N., Chen, G., et al. (2019). Interleukin-17 Regulates Neuron-Glial Communications, Synaptic Transmission, and Neuropathic Pain after Chemotherapy. Cel Rep. 29 (8), 2384–2397 e2385. doi:10.1016/j.celrep.2019.10.085
Lyman, G. H. (2009). Impact of Chemotherapy Dose Intensity on Cancer Patient Outcomes. J. Natl. Compr. Canc Netw. 7 (1), 99–108. doi:10.6004/jnccn.2009.0009
Ma, J., Kavelaars, A., Dougherty, P. M., and Heijnen, C. J. (2018). Beyond Symptomatic Relief for Chemotherapy-Induced Peripheral Neuropathy: Targeting the Source. Cancer 124 (11), 2289–2298. doi:10.1002/cncr.31248
Makin, T. R., and Flor, H. (2020). Brain (Re)organisation Following Amputation: Implications for Phantom Limb Pain. NeuroImage 218, 116943. doi:10.1016/j.neuroimage.2020.116943
Mannelli, L. D. C., Marcoli, M., Micheli, L., Zanardelli, M., Maura, G., Ghelardini, C., et al. (2015). Oxaliplatin Evokes P2X7-dependent Glutamate Release in the Cerebral Cortex: A Pain Mechanism Mediated by Pannexin 1. Neuropharmacology 97, 133–141. doi:10.1016/j.neuropharm.2015.05.037
Maruta, T., Nemoto, T., Hidaka, K., Koshida, T., Shirasaka, T., Yanagita, T., et al. (2019). Upregulation of ERK Phosphorylation in Rat Dorsal Root Ganglion Neurons Contributes to Oxaliplatin-Induced Chronic Neuropathic Pain. PloS one 14 (11), e0225586. doi:10.1371/journal.pone.0225586
Masocha, W. (2015). Astrocyte Activation in the Anterior Cingulate Cortex and Altered Glutamatergic Gene Expression during Paclitaxel-Induced Neuropathic Pain in Mice. PeerJ 3, e1350. doi:10.7717/peerj.1350
Masocha, W. (2016). Gene Expression Profile of Sodium Channel Subunits in the Anterior Cingulate Cortex during Experimental Paclitaxel-Induced Neuropathic Pain in Mice. PeerJ 4, e2702. doi:10.7717/peerj.2702
McLeary, F., Davis, A., Rudrawar, S., Perkins, A., and Anoopkumar-Dukie, S. (2019). Mechanisms Underlying Select Chemotherapeutic-Agent-Induced Neuroinflammation and Subsequent Neurodegeneration. Eur. J. Pharmacol. 842, 49–56. doi:10.1016/j.ejphar.2018.09.034
Melzack, R., and Wall, P. D. (1965). Pain Mechanisms: a New Theory. Science 150 (3699), 971–978. doi:10.1126/science.150.3699.971
Minami, T., Ichii, M., and Okazaki, Y. (1996b). Detection of Platinum in the Brain of Mice Treated with Cisplatin and Subjected to Short-Term Hypoxia. J. Pharm. Pharmacol. 48 (5), 505–509. doi:10.1111/j.2042-7158.1996.tb05962.x
Minami, T., Ichii, M., Okazaki, J., Kawaki, H., and Okazaki, Y. (1996a). Free Radical Scavengers Suppress the Accumulation of Platinum in the Cerebral Cortex. Biol. Trace Elem. Res. 55 (1–2), 1–7. doi:10.1007/bf02784163
Minami, T., Okazaki, J., Kawabata, A., Kawaki, H., and Okazaki, Y. (1996c). Lipopolysaccharide-induced Platinum Accumulation in the Cerebral Cortex after Cisplatin Administration in Mice: Involvement of Free Radicals. Environ. Toxicol. Pharmacol. 2 (4), 321–326. doi:10.1016/s1382-6689(96)00064-6
Minami, T., Okazaki, J., Kawabata, A., Kuroda, R., and Okazaki, Y. (1998). Penetration of Cisplatin into Mouse Brain by Lipopolysaccharide. Toxicology 130 (–-3), 107–113. doi:10.1016/s0300-483x(98)00103-6
Mols, F., Beijers, T., Lemmens, V., van den Hurk, C. J., Vreugdenhil, G., and van de Poll-Franse, L. V. (2013). Chemotherapy-Induced Neuropathy and its Association with Quality of Life Among 2- to 11-Year Colorectal Cancer Survivors: Results from the Population-Based PROFILES Registry. Jco 31 (21), 2699–2707. doi:10.1200/jco.2013.49.1514
Morioka, N., Kodama, K., Tomori, M., Yoshikawa, K., Saeki, M., Nakamura, Y., et al. (2019). Stimulation of Nuclear Receptor REV-ERBs Suppresses Production of Pronociceptive Molecules in Cultured Spinal Astrocytes and Ameliorates Mechanical Hypersensitivity of Inflammatory and Neuropathic Pain of Mice. Brain Behav. Immun. 78, 116–130. doi:10.1016/j.bbi.2019.01.014
Mullins, P. G., McGonigle, D. J., O'Gorman, R. L., Puts, N. A. J., Vidyasagar, R., Evans, C. J., et al. (2014). Current Practice in the Use of MEGA-PRESS Spectroscopy for the Detection of GABA. Neuroimage 86, 43–52. doi:10.1016/j.neuroimage.2012.12.004
Munn, Z., Peters, M. D., Stern, C., Tufanaru, C., McArthur, A., and Aromataris, E. (2018). Systematic Review or Scoping Review? Guidance for Authors when Choosing between a Systematic or Scoping Review Approach. BMC Med. Res. Methodol. 18 (1), 143. doi:10.1186/s12874-018-0611-x
Nagasaka, K., Yamanaka, K., Ogawa, S., Takamatsu, H., and Higo, N. (2017). Brain Activity Changes in a Macaque Model of Oxaliplatin-Induced Neuropathic Cold Hypersensitivity. Sci. Rep. 7 (1), 4305. doi:10.1038/s41598-017-04677-7
Nahman‐Averbuch, H., Granovsky, Y., Sprecher, E., Steiner, M., Tzuk‐Shina, T., Pud, D., et al. (2014). Associations between Autonomic Dysfunction and Pain in Chemotherapy‐induced Polyneuropathy. Eur. J. Pain 18 (1), 47–55. doi:10.1002/j.1532-2149.2013.00349.x
Nashawi, H., Masocha, W., Edafiogho, I. O., and Kombian, S. B. (2016). Paclitaxel Causes Electrophysiological Changes in the Anterior Cingulate Cortex via Modulation of the γ-Aminobutyric Acid-Ergic System. Med. Princ Pract. 25 (5), 423–428. doi:10.1159/000447775
Nassini, R., Gees, M., Harrison, S., De Siena, G., Materazzi, S., Moretto, N., et al. (2011). Oxaliplatin Elicits Mechanical and Cold Allodynia in Rodents via TRPA1 Receptor Stimulation. PAIN 152 (7), 1621–1631. doi:10.1016/j.pain.2011.02.051
Ng, W. P., Lee, K. O., Shen, L., Ong, J., Nyein Nyein, T. D., and Wilder-Smith, E. P. (2013). EMLA-induced Skin Wrinkling for the Detection of Diabetic Neuropathy. Front. Neurol. 4, 126. doi:10.3389/fneur.2013.00126
Nie, B., Liu, C., Bai, X., Chen, X., Wu, S., Zhang, S., et al. (2018). AKAP150 Involved in Paclitaxel-Induced Neuropathic Pain via Inhibiting CN/NFAT2 Pathway and Downregulating IL-4. Brain Behav. Immun. 68, 158–168. doi:10.1016/j.bbi.2017.10.015
Norcini, M., Vivoli, E., Galeotti, N., Bianchi, E., Bartolini, A., and Ghelardini, C. (2009). Supraspinal Role of Protein Kinase C in Oxaliplatin-Induced Neuropathy in Rat. Pain 146 (1-2), 141–147. doi:10.1016/j.pain.2009.07.017
Nudelman, K. N. H., McDonald, B. C., Wang, Y., Smith, D. J., West, J. D., O'Neill, D. P., et al. (2016). Cerebral Perfusion and Gray Matter Changes Associated with Chemotherapy-Induced Peripheral Neuropathy. Jco 34 (7), 677–683. doi:10.1200/jco.2015.62.1276
Onda, A., Hamba, M., Yabuki, S., and Kikuchi, S. (2002). Exogenous Tumor Necrosis Factor-α Induces Abnormal Discharges in Rat Dorsal Horn Neurons. Spine 27 (15), 1618–1624. doi:10.1097/00007632-200208010-00005
Özaktay, C., Cavanaugh, J., Asik, I., DeLeo, J., and Weinstein, J. (2002). Dorsal Root Sensitivity to Interleukin-1 Beta, Interleukin-6 and Tumor Necrosis Factor in Rats. Eur. Spine J. 11 (5), 467–475. doi:10.1007/s00586-002-0430-x
Pachman, D. R., Qin, R., Seisler, D. K., Smith, E. M. L., Beutler, A. S., Ta, L. E., et al. (2015). Clinical Course of Oxaliplatin-Induced Neuropathy: Results from the Randomized Phase III Trial N08CB (Alliance). Jco 33 (30), 3416–3422. doi:10.1200/jco.2014.58.8533
Park, H. J., Stokes, J. A., Corr, M., and Yaksh, T. L. (2014). Toll-like Receptor Signaling Regulates Cisplatin-Induced Mechanical Allodynia in Mice. Cancer Chemother. Pharmacol. 73 (1), 25–34. doi:10.1007/s00280-013-2304-9
Paulus, M. P., and Stein, M. B. (2010). Interoception in Anxiety and Depression. Brain Struct. Funct. 214 (5-6), 451–463. doi:10.1007/s00429-010-0258-9
Peng, P., Xi, Q., Xia, S., Zhuang, L., Gui, Q., Chen, Y., et al. (2012). Pregabalin Attenuates Docetaxel-Induced Neuropathy in Rats. J. Huazhong Univ. Sci. Technol. Med. Sci. 32 (4), 586–590. doi:10.1007/s11596-012-1001-y
Pike, C. T., Birnbaum, H. G., Muehlenbein, C. E., Pohl, G. M., and Natale, R. B. (2012). Healthcare Costs and Workloss burden of Patients with Chemotherapy-Associated Peripheral Neuropathy in Breast, Ovarian, Head and Neck, and Nonsmall Cell Lung Cancer. Chemother. Res. Pract. 2012, 913848. doi:10.1155/2012/913848
Prinsloo, S., Novy, D., Driver, L., Lyle, R., Ramondetta, L., Eng, C., et al. (2017). Randomized Controlled Trial of Neurofeedback on Chemotherapy-Induced Peripheral Neuropathy: A Pilot Study. Cancer 123 (11), 1989–1997. doi:10.1002/cncr.30649
Quartu, M., Carozzi, V. A., Dorsey, S., Serra, M. P., Poddighe, L., Picci, C., et al. (2014). Bortezomib Treatment Produces Nocifensive Behavior and Changes in the Expression of TRPV1, CGRP, and Substance P in the Rat DRG, Spinal Cord, and Sciatic Nerve. Biomed. Research International 2014. 39. doi:10.1155/2014/180428
Raichle, M. E. (2015). The Brain's Default Mode Network. Annu. Rev. Neurosci. 38, 433–447. doi:10.1146/annurev-neuro-071013-014030
Reddan, M. C., and Wager, T. D. (2018). Modeling Pain Using fMRI: from Regions to Biomarkers. Neurosci. Bull. 34 (1), 208–215. doi:10.1007/s12264-017-0150-1
Reeves, B. N., Dakhil, S. R., Sloan, J. A., Wolf, S. L., Burger, K. N., Kamal, A., et al. (2012). Further Data Supporting that Paclitaxel-Associated Acute Pain Syndrome Is Associated with Development of Peripheral Neuropathy. Cancer 118 (20), 5171–5178. doi:10.1002/cncr.27489
Sanacora, G., Gueorguieva, R., Epperson, C. N., Wu, Y.-T., Appel, M., Rothman, D. L., et al. (2004). Subtype-Specific Alterations of γ-Aminobutyric Acid and Glutamatein Patients with Major Depression. Arch. Gen. Psychiatry 61 (7), 705–713. doi:10.1001/archpsyc.61.7.705
Sanna, M. D., Ghelardini, C., and Galeotti, N. (2016). Altered Expression of Cytoskeletal and Axonal Proteins in Oxaliplatin-Induced Neuropathy. Pharmacology 97 (3-4), 146–150. doi:10.1159/000443898
Screnci, D., McKeage, M. J., Galettis, P., Hambley, T. W., Palmer, B. D., and Baguley, B. C. (2000). Relationships between Hydrophobicity, Reactivity, Accumulation and Peripheral Nerve Toxicity of a Series of Platinum Drugs. Br. J. Cancer 82 (4), 966–972. doi:10.1054/bjoc.1999.1026
Scuteri, A., Galimberti, A., Ravasi, M., Pasini, S., Donzelli, E., Cavaletti, G., et al. (2010). NGF Protects Dorsal Root Ganglion Neurons from Oxaliplatin by Modulating JNK/Sapk and ERK1/2. Neurosci. Lett. 486 (3), 141–145. doi:10.1016/j.neulet.2010.09.028
Secades, J. J., and Frontera, G. (1995). CDP-choline: Pharmacological and Clinical Review. Methods Find Exp. Clin. Pharmacol. 17 (Suppl. B), 1–54.
Secades, J. J., and Lorenzo, J. L. (2006). Citicoline: Pharmacological and Clinical Review, 2006 Update. Methods Find Exp. Clin. Pharmacol. 28 (Suppl. B), 1–56.
Seretny, M., Currie, G. L., Sena, E. S., Ramnarine, S., Grant, R., MacLeod, M. R., et al. (2014). Incidence, Prevalence, and Predictors of Chemotherapy-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis. Pain 155 (12), 2461–2470. doi:10.1016/j.pain.2014.09.020
Sharma, S., Venkitaraman, R., Vas, P. R., and Rayman, G. (2015). Assessment of Chemotherapy-Induced Peripheral Neuropathy Using the LDIFLARE Technique: a Novel Technique to Detect Neural Small Fiber Dysfunction. Brain Behav. 5 (7), e00354. doi:10.1002/brb3.354
Shidahara, Y., Natsume, T., Awaga, Y., Ogawa, S. y., Yamoto, K., Okamoto, S., et al. (2019). Distinguishing Analgesic Drugs from Non-analgesic Drugs Based on Brain Activation in Macaques with Oxaliplatin-Induced Neuropathic Pain. Neuropharmacology 149, 204–211. doi:10.1016/j.neuropharm.2019.02.031
Shidahara, Y., Ogawa, S., Nakamura, M., Nemoto, S., Awaga, Y., Takashima, M., et al. (2016). Pharmacological Comparison of a Nonhuman Primate and a Rat Model of Oxaliplatin‐induced Neuropathic Cold Hypersensitivity. Pharmacol. Res. Perspect. 4 (1), e00216. doi:10.1002/prp2.216
Siegel, E. H., Sands, M. K., Van den Noortgate, W., Condon, P., Chang, Y., Dy, J., et al. (2018). Emotion Fingerprints or Emotion Populations? A Meta-Analytic Investigation of Autonomic Features of Emotion Categories. Psychol. Bull. 144 (4), 343–393. doi:10.1037/bul0000128
Sklerov, M., Dayan, E., and Browner, N. (2019). Functional Neuroimaging of the central Autonomic Network: Recent Developments and Clinical Implications. Clin. Auton. Res. 29 (6), 555–566. doi:10.1007/s10286-018-0577-0
Slivicki, R. A., Saberi, S. A., Iyer, V., Vemuri, V. K., Makriyannis, A., and Hohmann, A. G. (2018). Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception without Enhancing Effects of Morphine on Gastrointestinal Transit. J. Pharmacol. Exp. Ther. 367 (3), 551–563. doi:10.1124/jpet.118.252288
Slivicki, R. A., Xu, Z., Mali, S. S., and Hohmann, A. G. (2019). Brain Permeant and Impermeant Inhibitors of Fatty-Acid Amide Hydrolase Suppress the Development and Maintenance of Paclitaxel-Induced Neuropathic Pain without Producing Tolerance or Physical Dependence In Vivo and Synergize with Paclitaxel to Reduce Tumor Cell Line Viability In Vitro. Pharmacol. Res. 142, 267–282. doi:10.1016/j.phrs.2019.02.002
Smith, E. M. L., Pang, H., Cirrincione, C., Fleishman, S., Paskett, E. D., Ahles, T., et al. (2013). Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients with Chemotherapy-Induced Painful Peripheral Neuropathy. Jama 309 (13), 1359–1367. doi:10.1001/jama.2013.2813
Smith, T., and Nicholson, R. A. (2007). Review of Duloxetine in the Management of Diabetic Peripheral Neuropathic Pain. Vasc. Health Risk Manag. 3 (6), 833–844.
Sorkin, L. S., Xiao, W.-H., Wagner, R., and Myers, R. R. (1997). Tumour Necrosis Factor-α Induces Ectopic Activity in Nociceptive Primary Afferent Fibres. Neuroscience 81 (1), 255–262. doi:10.1016/s0306-4522(97)00147-4
Staff, N. P., Grisold, A., Grisold, W., and Windebank, A. J. (2017). Chemotherapy-induced Peripheral Neuropathy: A Current Review. Ann. Neurol. 81 (6), 772–781. doi:10.1002/ana.24951
Starobova, H., and Vetter, I. (2017). Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy. Front. Mol. Neurosci. 10, 174. doi:10.3389/fnmol.2017.00174
Stine, C., Coleman, D. L., Flohrschutz, A. T., Thompson, A. L., Mishra, S., Blagg, B. S., et al. (2020). Heat Shock Protein 90 Inhibitors Block the Antinociceptive Effects of Opioids in Mouse Chemotherapy-Induced Neuropathy and Cancer Bone Pain Models. Pain 161 (8), 1798–1807. doi:10.1097/j.pain.0000000000001886
Szudy‐Szczyrek, A., Mlak, R., Bury‐Kamińska, M., Mielnik, M., Podgajna, M., Kuśmierczuk, K., et al. (2020). Serum Brain‐derived Neurotrophic Factor (BDNF) Concentration Predicts Polyneuropathy and Overall Survival in Multiple Myeloma Patients. Br. J. Haematol. 191 (1), 77–89. doi:10.1111/bjh.16862
Ta, L. E., Bieber, A. J., Carlton, S. M., Loprinzi, C. L., Low, P. A., and Windebank, A. J. (2010). Transient Receptor Potential Vanilloid 1 Is Essential for Cisplatin-Induced Heat Hyperalgesia in Mice. Mol. Pain 6, 15. doi:10.1186/1744-8069-6-15
Takamura, T., and Hanakawa, T. (2017). Clinical Utility of Resting-State Functional Connectivity Magnetic Resonance Imaging for Mood and Cognitive Disorders. J. Neural Transm. 124 (7), 821–839. doi:10.1007/s00702-017-1710-2
Terasawa, Y., and Umeda, S. (2017). The Impact of Interoception on Memory. Memory in a Social Context. Berlin: Springer, 165–178. doi:10.1007/978-4-431-56591-8_9
Thibault, K., Calvino, B., Dubacq, S., Roualle-de-Rouville, M., Sordoillet, V., Rivals, I., et al. (2012). Cortical Effect of Oxaliplatin Associated with Sustained Neuropathic Pain: Exacerbation of Cortical Activity and Down-Regulation of Potassium Channel Expression in Somatosensory Cortex. PAIN 153 (8), 1636–1647. doi:10.1016/j.pain.2012.04.016
Thibault, K., Calvino, B., Rivals, I., Marchand, F., Dubacq, S., McMahon, S. B., et al. (2014). Molecular Mechanisms Underlying the Enhanced Analgesic Effect of Oxycodone Compared to Morphine in Chemotherapy-Induced Neuropathic Pain. PLoS ONE 9 (3), e91297. doi:10.1371/journal.pone.0091297
Tokuda, T., Yoshimoto, J., Shimizu, Y., Okada, G., Takamura, M., Okamoto, Y., et al. (2018). Identification of Depression Subtypes and Relevant Brain Regions Using a Data-Driven Approach. Scientific Rep. 8 (1), 1–13. doi:10.1038/s41598-018-32521-z
Toma, W., Kyte, S. L., Bagdas, D., Alkhlaif, Y., Alsharari, S. D., Lichtman, A. H., et al. (2017). Effects of Paclitaxel on the Development of Neuropathy and Affective Behaviors in the Mouse. Neuropharmacology 117, 305–315. doi:10.1016/j.neuropharm.2017.02.020
Toyama, S., Shimoyama, N., and Shimoyama, M. (2017). The Analgesic Effect of Orexin-A in a Murine Model of Chemotherapy-Induced Neuropathic Pain. Neuropeptides 61, 95–100. doi:10.1016/j.npep.2016.12.007
Verstappen, C. C. P., Heimans, J. J., Hoekman, K., and Postma, T. J. (2003). Neurotoxic Complications of Chemotherapy in Patients with Cancer. Drugs 63 (15), 1549–1563. doi:10.2165/00003495-200363150-00003
Vezzani, A., and Viviani, B. (2015). Neuromodulatory Properties of Inflammatory Cytokines and Their Impact on Neuronal Excitability. Neuropharmacology 96, 70–82. doi:10.1016/j.neuropharm.2014.10.027
Vichaya, E. G., Chiu, G. S., Krukowski, K., Lacourt, T. E., Kavelaars, A., Dantzer, R., et al. (2015). Mechanisms of Chemotherapy-Induced Behavioral Toxicities. Front. Neurosci. 9, 131. doi:10.3389/fnins.2015.00131
Wang, X.-M., Lehky, T. J., Brell, J. M., and Dorsey, S. G. (2012). Discovering Cytokines as Targets for Chemotherapy-Induced Painful Peripheral Neuropathy. Cytokine 59 (1), 3–9. doi:10.1016/j.cyto.2012.03.027
Waseem, M., Kaushik, P., Tabassum, H., and Parvez, S. (2018). Role of Mitochondrial Mechanism in Chemotherapy-Induced Peripheral Neuropathy. Cdm 19 (1), 47–54. doi:10.2174/1389200219666171207121313
Wasilewski, A., and Mohile, N. (2020). Meet the Expert: How I Treat Chemotherapy-Induced Peripheral Neuropathy. J. Geriatr. Oncol. 12 (1), 1–5. doi:10.1016/j.jgo.2020.06.008
Webster, R. G., Brain, K. L., Wilson, R. H., Grem, J. L., and Vincent, A. (2005). Oxaliplatin Induces Hyperexcitability at Motor and Autonomic Neuromuscular Junctions through Effects on Voltage-Gated Sodium Channels. Br. J. Pharmacol. 146 (7), 1027–1039. doi:10.1038/sj.bjp.0706407
Weng, H. R., Cordella, J. V., and Dougherty, P. M. (2003). Changes in Sensory Processing in the Spinal Dorsal Horn Accompany Vincristine-Induced Hyperalgesia and Allodynia. Pain 103 (1-2), 131–138. doi:10.1016/s0304-3959(02)00445-1
Wickham, R. J. (2020). Revisiting the Physiology of Nausea and Vomiting-Challenging the Paradigm. Support Care Cancer 28 (1), 13–21. doi:10.1007/s00520-019-05012-8
Wilder-Smith, E. P. V. (2015). Stimulated Skin Wrinkling as an Indicator of Limb Sympathetic Function. Clin. Neurophysiol. 126 (1), 10–16. doi:10.1016/j.clinph.2014.08.007
Win, S., Salciccioli, L., Kamran, H., Baweja, P., Stewart, M., and Lazar, J. M. (2010). Water Immersion-Induced Skin Wrinkling Is Related to Heart Rate Variability. Cardiology 116 (4), 247–250. doi:10.1159/000316043
Woolf, C. J., Allchorne, A., Safieh-Garabedian, B., and Poole, S. (1997). Cytokines, Nerve Growth Factor and Inflammatory Hyperalgesia: the Contribution of Tumour Necrosis Factor α. Br. J. Pharmacol. 121 (3), 417–424. doi:10.1038/sj.bjp.0701148
Xiao, W., Boroujerdi, A., Bennett, G. J., and Luo, Z. D. (2007). Chemotherapy-evoked Painful Peripheral Neuropathy: Analgesic Effects of Gabapentin and Effects on Expression of the Alpha-2-delta Type-1 Calcium Channel Subunit. Neuroscience 144 (2), 714–720. doi:10.1016/j.neuroscience.2006.09.044
Xu, D., Zhao, H., Gao, H., Zhao, H., Liu, D., and Li, J. (2018). Participation of Pro-inflammatory Cytokines in Neuropathic Pain Evoked by Chemotherapeutic Oxaliplatin via central GABAergic Pathway. Mol. pain 14, 1744806918783535. doi:10.1177/1744806918783535
Yadav, R., Yan, X., Maixner, D. W., Gao, M., and Weng, H.-R. (2015). Blocking the GABA Transporter GAT-1 Ameliorates Spinal GABAergic Disinhibition and Neuropathic Pain Induced by Paclitaxel. J. Neurochem. 133 (6), 857–869. doi:10.1111/jnc.13103
Zajaczkowska, R., Kocot-Kepska, M., Leppert, W., Wrzosek, A., Mika, J., and Wordliczek, J. (2019). Mechanisms of Chemotherapy-Induced Peripheral Neuropathy. Int. J. Mol. Sci. 20 (6).
Zaręba, P., Gryzło, B., Malawska, K., Sałat, K., Höfner, G. C., Nowaczyk, A., et al. (2020). Novel Mouse GABA Uptake Inhibitors with Enhanced Inhibitory Activity toward mGAT3/4 and Their Effect on Pain Threshold in Mice. Eur. J. Med. Chem. 188, 111920. doi:10.1016/j.ejmech.2019.111920
Zhang, H., Boyette-Davis, J. A., Kosturakis, A. K., Li, Y., Yoon, S.-Y., Walters, E. T., et al. (2013). Induction of Monocyte Chemoattractant Protein-1 (MCP-1) and its Receptor CCR2 in Primary Sensory Neurons Contributes to Paclitaxel-Induced Peripheral Neuropathy. J. Pain 14 (10), 1031–1044. doi:10.1016/j.jpain.2013.03.012
Zhang, H., and Dougherty, P. M. (2014). Enhanced Excitability of Primary Sensory Neurons and Altered Gene Expression of Neuronal Ion Channels in Dorsal Root Ganglion in Paclitaxel-Induced Peripheral Neuropathy. AnesthesiologyThe J. Am. Soc. Anesthesiologists 120 (6), 1463–1475. doi:10.1097/aln.0000000000000176
Zhang, H., Li, Y., de Carvalho-Barbosa, M., Kavelaars, A., Heijnen, C. J., Albrecht, P. J., et al. (2016). Dorsal Root Ganglion Infiltration by Macrophages Contributes to Paclitaxel Chemotherapy-Induced Peripheral Neuropathy. J. Pain 17 (7), 775–786. doi:10.1016/j.jpain.2016.02.011
Zhang, Y., Brewer, A. L., Nelson, J. T., Smith, P. T., Shirachi, D. Y., and Quock, R. M. (2019). Hyperbaric Oxygen Produces a Nitric Oxide Synthase-Regulated Anti-allodynic Effect in Rats with Paclitaxel-Induced Neuropathic Pain. Brain Res. 1711, 41–47. doi:10.1016/j.brainres.2019.01.009
Zhao, M., Isami, K., Nakamura, S., Shirakawa, H., Nakagawa, T., and Kaneko, S. (2012). Acute Cold Hypersensitivity Characteristically Induced by Oxaliplatin Is Caused by the Enhanced Responsiveness of TRPA1 in Mice. Mol. Pain 8, 55. doi:10.1186/1744-8069-8-55
Zheng, H., Xiao, W. H., and Bennett, G. J. (2011). Functional Deficits in Peripheral Nerve Mitochondria in Rats with Paclitaxel- and Oxaliplatin-Evoked Painful Peripheral Neuropathy. Exp. Neurol. 232 (2), 154–161. doi:10.1016/j.expneurol.2011.08.016
Keywords: chemotherapy, neuropathy, brain, clinical, translational
Citation: Omran M, Belcher EK, Mohile NA, Kesler SR, Janelsins MC, Hohmann AG and Kleckner IR (2021) Review of the Role of the Brain in Chemotherapy-Induced Peripheral Neuropathy. Front. Mol. Biosci. 8:693133. doi: 10.3389/fmolb.2021.693133
Received: 09 April 2021; Accepted: 24 May 2021;
Published: 11 June 2021.
Edited by:
Andrea Stojakovic, Mayo Clinic, United StatesReviewed by:
Patrick M. Dougherty, University of Texas MD Anderson Cancer Center, United StatesFernando Lopes, McGill University, Canada
Copyright © 2021 Omran, Belcher, Mohile, Kesler, Janelsins, Hohmann and Kleckner. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ian R. Kleckner, SWFuX0tsZWNrbmVyQFVSTUMuUm9jaGVzdGVyLmVkdQ==